Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
PD 
PD 
Protocol Version/Date: GILEAU 
CLINICAL STUDY PROTOCOL 
A Proo f of Concept , Open- Label Study Evaluating the Safety , 
Tolerability, and Efficacy ofMonotherapy and Comb ination Regimens in 
Subjects with Nonalcoho lic Steatohepat itis (NAS H) 
[COMPANY_009] Sciences , Inc. 
[ADDRESS_747595] 
Foster City, CA [ZIP_CODE] 
141683 
Not App licable 
NCT0398707 4 
Nonalcoho lic steatohepat itis (NAS H) 
GS-US-454-5533 
Name : 
[CONTACT_10880] : 
Mob ile: 
Fax: 
Ema il: 
Name : 
[CONTACT_10880] : 
Mob ile: 
Fax: 
Ema il: 
Original: 
Amendment 1 : 
Amendment 2: PD 
PD 
PD 
PD 
YLJ 
PD PD 
PD PD 
YLJ 
17May2 [ADDRESS_747596] 2019 
22 October 2019 
This study w ill be conducted m1der US Food & Drug Ad mini stration IND regulations 
(21 CFR Part 312). 
CONFIDENTIALITY STATEMENT 
The infonnat ion conta ined in this docmnent, parti cularly m1pub lished data, is the property or 
under contro l of [COMPANY_009] Sciences, Inc., and is provi ded to you in confidence as an invest igator, 
potent ial investigator, or consultant, for review by [CONTACT_10825], your staff, and an applicable 
Institutional Review Boar d or Indepen dent Ethics Co1mnitt ee. The infonnation is only to be 
used by [CONTACT_569922] l. You will not disclose any of the infonnat ion to others wi thout 
written author ization from [COMPANY_009] Sciences, Inc., except to the extent necessary to obtain 
infonne d consent from those persons to whom the drug may be admini stere d. 
Protocol GS-US-454-[ADDRESS_747597] OF IN-TEXT FI GURES ...................................................................................................................................... 6 
PROTO COL SYN OPSIS .............................................................................................................................................. 7 
GLOSSARY O F ABBREVIAT IONS AND D EFINITION OF TE RMS .................................................................... 18 
I. INTRO DUCTION .............................................................................................................................................. 23 
1.1. Back ground ............................................................................................................................................ 23 
1.2. Gene ral Information for Semaglutide ..................................................................................................... 24 
1.2.1. Gene ral Infor mation ............................................................................................................. 24 
1.2.2. Pre-C linical Studies .............................................................................................................. 25 
1.2.3. C linical Trial s with Semaglutide .......................................................................................... 25 
1.3. Gene ral Information for Cilofexor ......................................................................................................... 27 
1.3.1. C ilofexor .............................................................................................................................. 27 
1.3 .2. N onclinical Pharmacolo gy and Toxicolo gy ......................................................................... 27 
1.3.3. C linical Trial s ofCilofexor .................................................................................................. 29 
1.3.4. A Phase I, Open-Label, P arall el-Grou p, Adaptive, Single-D ose Study to 
Evaluate the Phannacokin etics and Pharmacodynamic s ofCilofexor in 
Subj ects wi th Normal and Impaired H epatic F unction 
(Study GS-US-402-3885) ..................................................................................................... 29 
1.4. General Information for Firsocostat ....................................................................................................... 34 
1.4.1. F irsocos tat ............................................................................................................................ 34 
1.4.2. N onclini cal Pharmacology ................................................................................................... 34 
1.4.3. N onclini cal Toxicology ........................................................................................................ 35 
1.4.4. N onclini cal Pharmacokinetics .............................................................................................. 36 
1.4.5. C linical Trial s of Firsocostat ................................................................................................ 36 
1.4.6. S tudy GS-US-426-3988 : A Phase I Open-Label, Pa rallel-G roup, 
Single-Do se Study to Evaluate the Pharmacokinetics of Fi rsocostat or 
Fenofibrate in Subj ects wi th Normal and Impaired H epatic F unction ................................. [ADDRESS_747598] Selection ............................................................................................ 52 
CON FIDENT IAL Page 2 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 3 22 October [ZIP_CODE].2. Inclusion Criteria .................................................................................................................................... 52
4.3. Exclusion Criteria ................................................................................................................................... 53
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 56
5.1. Randomization ....................................................................................................................................... 56
5.2. Description and Handling of Semaglutide 3.0 mg/mL ........................................................................... 56
5.2.1. PDS290 pen -injector for Semaglutide for use in Clinical Trials .......................................... 57
5.2.2. Storage and Handling ........................................................................................................... 58
5.2.3. Shelf -life and in -use time for Semaglutide in PDS290 ........................................................ 58
5.3. Description and Handling of Cilofexor (GS -9674) ................................................................................ 58
5.3.1. Form ulation .......................................................................................................................... 58
5.3.2. Packagi ng and Labeling ....................................................................................................... 58
5.3.3. Storage and Handling ........................................................................................................... 58
5.4. Description and Handling of Firsocostat (GS -0976) .............................................................................. [ADDRESS_747599] (IMP) and 
Devices ................................................................................................................................................... [ADDRESS_747600] Enrollment and Treatment Assignment ..................................................................................... 65
6.2. Screening Assessments .......................................................................................................................... 65
6.2.1. Screening Visit ..................................................................................................................... 65
6.3. Pretreatment Assessments ...................................................................................................................... 67
6.3.1. Day -14 Visit ........................................................................................................................ 67
6.3.2. Day -11 and Day -7 Visits (± 1 day) .................................................................................... 68
6.4. Treatment Assessments .......................................................................................................................... 69
6.4.1. Day 1 Visit ........................................................................................................................... 69
6.4.2. Day 7 (Week 1) Visit (± 3 days) .......................................................................................... 70
6.4.3. Day 28 (Week 4) Visit (± 3 days) ........................................................................................ 71
6.4.4. Day 56 (Week 8) Visit (± 3 days) ........................................................................................ 71
6.4.5. Day 84 (Week 12) Visit (± 3 days) ...................................................................................... 72
6.4.6. Day 112 (Week 16) Visit (± 3 days) .................................................................................... 74
6.4.7. Day 140 (Week 20) Visit (± 3 days) .................................................................................... 74
6.4.8. Day 154 (Week 22) Visit (± 1 day) ...................................................................................... 75
6.4.9. Day 157 (Week 22 Day 2) and Day 161 (Week 23) Visit (± 1 day) .................................... 76
6.4.10. Day 168 (Week 24) / End of Treatment Visit ( ± 3 days) ..................................................... 76
6.4.11. Early Termination (ET) Visit ............................................................................................... 78
6.4.12. Unscheduled Visits ............................................................................................................... 79
6.5. Posttreatment Assessments .................................................................................................................... 79
6.5.1. Telephone Follow -Up Visit (± 3 days) ................................................................................. 79
6.6. Criteria for Discontinuation of Study Treatment .................................................................................... 80
6.7. Assessments for Premature Discontinuation from Study ....................................................................... 81
6.8. Interruption of Study Drug ..................................................................................................................... 82
6.9. End of Study ........................................................................................................................................... 82
6.10. Descriptio n of Assessments ................................................................................................................... 82
6.10.1. Clinical Laboratory Analytes ............................................................................................... 82
6.10.2. Creatinine Clearance/eGFR .................................................................................................. 83
6.10.3. Child- Pugh (CP) Score ......................................................................................................... 83
6.10.4. MRE and MRI -PDFF ........................................................................................................... 84
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. Final 
Amendment2 
6.10.5. 
6.10.6. 
6.10.7. 
6.10.8. 
6.10.9. 
6.10.10. 
6. 10.11. 
6.10.12. FibroScan ® ........................................................................................................................... 85 
Electrocar diogram ................................................................................................................ 85 
Medical History .................................................................................................................... 85 
Physical Examination ........................................................................................................... 85 
Fundus Exami nation ............................................................................................................. 86 
Vital Signs ............................................................................................................................ 86 
Pregnancy Testing ................................................................................................................ 86 
Health Related ual i of Life HR oL Measures ............................................................. 87 
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ............................................................................... 88 
7. I. Definitions of Adverse Events, Adverse Reactions, and Serio us Ad verse Events ................................. 88 
7. I. I. Adverse Events ..................................................................................................................... 88 
7 .1.2. Serio us Adverse Events ........................................................................................................ 88 
7.2. Assessment of Adverse Events and Serio us Adverse Events ................................................................. 89 
7 .2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 90 
7 .2.2. Assessment of Severity ........................................................................................................ 90 
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serio us 
Adverse Events to [COMPANY_009] ....................................................................................................................... 91 
7.4. [COMPANY_009] Reporting Requirements ............................................................................................................. 92 
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serio us Adverse Events .......................................................................................................................... 93 
7.6. Toxicity Management ............................................................................................................................ 93 
7 .6.1. Observation for Drug Induced Liver lnju1y (DILi) .............................................................. 93 
7.6.2. Close Observation ................................................................................................................ 94 
7.6.3. CP Score ............................................................................................................................... 96 
7 .6.4. Hypertriglyceridemia ............................................................................................................ 96 
7.6.5. Pruritus Management ........................................................................................................... 97 
7.7. Special Situatio ns Reports ...................................................................................................................... 97 
7.7.1. Definitions of Special Situations .......................................................................................... 97 
7.7.2. Instmctions for Reporting Special Situations ....................................................................... 98 
8. STA TIS TI CAL CONSIDERATIONS .............................................................................................................. I 00 
8.1. 
8.2. 
8.3. 
8.4. 
8.5. 
8.6. 
8.7. 
8.8. 
8.9. 8.
10. Analysis Objectives and Endpoints ...................................................................................................... I 00 
8.1.1. An alysis Objectives ............................................................................................................ I 00 
8.1.2. Primar End oint ............................................................................................................... I 00 
. ysis Conventio ns ........................................................................................................................... I I 
8.2.1. An alysis Sets ...................................................................................................................... IO I 
8.2.2. Interim Analysis ................................................................................................................. I 02 
Data Handling Conventions ................................................................................................................. I 02 
Demographic Data and Baseline Characteristics ................................................................................. I 02 ir::,;:. :;, :o, 
8.6.1. Extent of Expos ure ............................................................................................................. I [ADDRESS_747601] (IRB) Review and Approval ................................................... [ADDRESS_747602] Accountability and Return ........................................... 108
9.1.9. Inspections .......................................................................................................................... 108
9.1.10. Protocol Compliance .......................................................................................................... 109
9.2. Sponsor Responsibilities ...................................................................................................................... 109
9.2.1. Protocol Modifications ....................................................................................................... 109
9.2.2. Study Report and Publications ........................................................................................... 109
9.3. Joint Investigator/Sponsor Resp onsibilities ......................................................................................... 110
9.3.1. Payment Reporting ............................................................................................................. 110
9.3.2. Access to Information for Monitoring ................................................................................ 110
9.3.3. Access to Information for Auditing or Inspections ............................................................ 110
9.3.4. Study Discontinuation ........................................................................................................ 110
10. REFERENCES ................................................................................................................................................. 111
11. APPENDICES .................................................................................................................................................. 114
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................. 115
Appendix 2. Study Procedures Table ........................................................................................................ 116
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 120
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) ............................................ [ADDRESS_747603] OF IN -TEXT TABL ES
Table 1-1. GS-US-402-3885: Preliminary Cilofexor, GS -716070, and GS -1056756 PK 
Parameters Following a Single Dose of Cilofexor 30 mg or 10 mg in Subjects with 
Hepatic Impairment or Normal Hepatic Function ................................
.................................. 32
Table 1-2. Preliminary Pharmacokinetic Results from Study GS -US-426-4074 Evaluating 
DDIs with Firsocostat (20 mg or 50 mg)................................
................................................ 39
Table 1-3. GS-US-426-3988: Preliminary Firsocostat and GS -[ADDRESS_747604] OF IN -TEXT FIGU RES
Figure 3-1. Overall Study Design ............................................................................................................. 48
Figure 7-1. On-Treatment ALT/AST Monitoring Requiring Close Observation ...................................... 94
Figure 7-2. On-Treatment Monitoring Requiring Withholding of Study Drugs ....................................... 95
Figure 7-3. Algorithm for Monitoring and Treatment of Hypertriglyceridemia ....................................... 96
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
Study Title: 
IND Number: 
EudraCT Number: 
Clinical Trials. gov 
Identifier: 
Study Centers 
Planned: 
Objecti ves: 
CONFI DENT IAL PROTOCOL SYNOP SIS 
[COMPANY_009] Sciences , Inc. 
[ADDRESS_747605]. 
Foster City , CA [ZIP_CODE] [LOCATION_003] Final 
Amendment2 
A Proof of Concept, Open-Labe l Study Evaluating the Safety, 
Tolerability, and Efficacy of Mono therapy and Comb ination 
Regimens in Subjects with Nona lcoho lic Steatohepat itis (NASH) 
141683 
Not Applicable 
[STUDY_ID_REMOVED] 
Approx imate ly 20 centers in the [LOCATION_002] 
The primary objective of this study is as follows: 
• To evaluate the safety and tolerability of study drug(s) in subjects 
with NASH . 
I 
I 
I I I 
Page 7 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 8 22 October 2019Study Design: This is a proof of concept, open -label stud y evaluating the safet y, 
tolerability , and efficacy  of monotherapy  and combination regimens 
in subjects with NASH.
Subjects meeting the study ’s entry  criteria will be randomly  assigned 
in a 1:1:1:1:1 ratio to 1 of 5 treatment groups, with approximately  
20subjects in each group, as shown in the figure below:
Randomization will be stratified b y the presence or absence of 
type 2 diabetes mellitus, as determined by  [CONTACT_569923] 
(hemoglobin A1c [HbA1c] ≥ 6.5%).
Number of 
Subjects Planned:Approximately  100 Subjects
Target Population: Males and non- pregnant, non -lactating females between 18 -75years 
of age with NASH as assessed b y historical liver biopsy , and/or 
noninvasive tests.
Duration of 
Treatment:Subjects will be treated for up to 24 weeks 
Duration of Study :Participation in the study can last up to 35 weeks, which includes a 
2-week Screening period, a 2 -week Pre -Treatment period, a 24 -week 
Treatment period, and a 7- week Follow -Up period. 
    
  
 
  
   
  
      
 
  
      
      
  
      
      
  
      
      
  
      
        
    
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 9 22 October 2019Diagnosis and 
Main Eligibility  
Criteria:Key Inclusion Criteria:
1) Males and females between 18 -75years of age; inclusive based 
on the date of the Screening Visit;
2)Willing and able to provide informed consent prior to any  study  
specific procedures being performed;
3)Subjects must meet all of the following conditions (a-d) OR (e) :
a.Clinical diagnosis of nonalcoholic fatt y liver disease 
(NAFLD) ;
b.Screening FibroTest®< 0.75, unless all previous historical 
liver biopsies do not reveal cirrhosis. In subjects with 
Gilbert’s sy ndrome or hemoly sis, FibroTest®will be 
calculated using direct bilirubin instead of total bilirubin;
c.Screening MRI -PDFF with ≥ 10% steatosis, as a ssessed b y 
the central reader . Historical MRI -PDFF within 4 weeks of 
the date of the Screening Visit may  be used if deemed 
acceptable b y the central reader ;
d.Screening FibroScan®with liver stiffness ≥ 7 kPa. Historical 
FibroScan® within 4 weeks of the date of the Screening Visit 
is acceptable ;
OR
e.Anhistorical liver biopsy within 6 months of the date of the 
Screening V isit consistent with NASH (defined as the 
presence of steatosis, inflammation, and ballooning) with 
stage 2 -3 fibrosis according to the NASH Clinical Research 
Network (CRN) classification (or equivalent) . Report will be
reviewed b y the Medical Monitor ;
4)Subject has the following laboratory  parameters at the Screening 
Visit, as determined b y the central laboratory:
a.Alanine aminotransferase (ALT) ≤ [ADDRESS_747606] ;
b.Estimated glomerular filtration rate ( eGFR )≥ 30 
milliliter/minute (mL /min), as calculated b y the MDRD study 
equation ;
c.HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c 
is unable to be resulted) ;
d. International normalized ratio ( INR)≤ 1.2, unless due to 
therapeutic anti -coagulation therap y;
e.Platelet count ≥ 100,000/ μL;
f.Total bilirubin < 1.[ADDRESS_747607] unless alternate etiology  such as 
Gilbert’s sy ndrome present ;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 10 22 October 2019g.Calcitonin ≤ 100 ng/L ;
5)Body Mass Index (BMI) > 23 kg/m2and bod y weight of > 60 kg ;
6)
A negative serum pregnancy  test is required for female subjects
of childbearing potential as defined in Appendix 3.
7)Male subjects and female subjects of childbearing potential who 
engage in heterosexual intercourse must agree to use protocol 
specified method(s) of contraception as described in Appendix 3.
Key Exclusion Criteria:
1) Documented weight loss > 5 % within 6 months of the date of the 
Screening Visit; 
2)Any historical liver biopsy  consistent with cirrhosis;
3) Pregnant or lactating females;
4) Alcohol consumption greater than 21 oz/week for males or 
14oz/week for females (1oz/30 mL of alcohol is present in 
112oz/360 mL beer, 1 4oz/120 mL  glass of wine, and a 
1oz/30 mL measure of 40% proof alcohol);
5) Positive urine screen for amphetamines, cocaine or opi[INVESTIGATOR_858] 
(ie,heroin, morphine) at Screening. Subjec ts on stable methadone 
or buprenorphine maintenance treatment for at least 6 months 
prior to the date of Screening Visit may  be included in the study . 
Subjects with a positive urine drug screen due to prescription 
opi[INVESTIGATOR_2480] -based or amphetamine -based medication are eligible if the 
prescription and diagnosis are reviewed and approved by  [CONTACT_1275];
6)Any history  of decompensated liver disease, including ascites, 
hepatic encephalopath y, or variceal bleeding;
7)Other causes of liver disease, including but not limited to: 
alcoholic liver disease, hepatitis B, hepatit is C, autoimmune 
disorders (eg, primary  biliary  cholangitis [PBC], primary  
sclerosing cholangitis [PS C], autoimmune hepatitis), 
drug-induced hepatotoxicity , Wilson disease, clinically  
significant iron overload, or alpha -1-antitry spin deficiency  
requiring treatment;
8)History  of liver transplantation;
9)History  of hepatocellular carcinoma;
10)Weight reduction surgery in the past 2 y ears or planned during 
the study ;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 11 22 October 201911)Chronic hepatitis B (HBsAg positive);
12)Chronic hepatitis C (HCV RNA positive). Subjects cured of HCV 
infection less than 2 years prior to the date of the Screening Visit 
are not eligible;
13)HIV Ab positive;
14)Unstable cardiovascular disease as defined b y any of the 
following:
a.Unstable angina, m yocardial infarction, coronary  artery  
by[CONTACT_569924] y within 6 months 
prior to the date of the Screening Visit;
b. Transient ischemic attack or cerebrovascular accident within 
6 months prior to the date of the Screening Visit;
c.Sympto matic obstructive valvular heart disease or 
hypertrophic cardiom yopathy;
d.Symptomatic congestive heart failure;
e.Uncontrolled or recurrent ventricular tach ycardia or other 
arrhythmia requiring an automatic implantable cardioverter 
defibrillator (AICD). Stabl e, controlled atrial fibrillation is 
allowed;
f.An emergency  room visit or hospi[INVESTIGATOR_569892] 6 months prior to the date of the 
Screening Visit;
15)History  of a malignancy  within 5 y ears of the date of the 
Screening Visi t with the following exceptions:
a.Adequatel y treated carcinoma in situ of the cervix ;
b.Adequatel y treated basal or squamous cell cancer or other 
localized non- melanoma skin cancer ;
16)
Presence of acute pancreatitis within the past 180 day s prior to 
the date of the Screening Visit;
17)History  or presence of chronic pancreatitis;
18)Presence or history  of type 1 diabetes mellitus;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 12 22 October 201919)For subjects with t ype 2 diabetes diagnosed prior to the date of 
the Screening Visit OR on S creening Visit labs 
(defined asHbA1c ≥6.5%), subjects must have no evidence of 
uncontrolled and potentially  unstable retinopathy  or maculopathy  
as determined b y: 
a.A fundus exam performed in the [ADDRESS_747608]’s visual function since this historical fundus exam in 
the opi[INVESTIGATOR_871], then the fundus exam must be 
repeated;
OR
b.A fundus exam performed between the date of the Screening 
Visit and Enrollment (Day  -14) 
Pharmacological pupil- dilation is a requirement in both of the 
above cases unless using a digital fundus photography  camera 
specified for non- dilated examination;
20)Personal or first degree relative(s) history  of multiple endocrine 
neoplasia ty pe 2 or medullary  thyroid carcinoma;
21)Treatment with GLP -1 RAs in the period from 90 days prior to 
the date of the Screening Visit;
22)Subjects on Vitamin E regimen ≥800 international units ( IU)/day 
must be on a stable dose (defined as no changes in prescribed 
dose, new Vitamin E containing medications, or discontinuation)
for at least 180 day s prior to the date of the Screening Visit and in 
the period between the date of the Screening Visit and Enrollment 
(Day  -14);
23)Subjects on antidiabetic medications must be on a stable dose for 
at least 90 day s prior to the date of the Screening Visit and in the 
period between the date of the Screening Visit and Enrollment 
(Day  -14); 
24)Use of an y prohibited concomitant medications as described in 
Section 5.6;
25)Any investigational medication or device within 30 day s or 
within 5 half -
lives of the prior investigational agent (whichever is 
longer) prior to the date of the Screening Visit throughout the 
study  (e.g., obeticholic acid, elafibranor, and cenicriviroc) is 
prohibited;
26)Known hy persensitivity  to the study  drug, the metabolites, or 
formulation excipi[INVESTIGATOR_841].
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 13 22 October 2019Study  Procedures/
Frequency :After signing the informed consent form (ICF), subjects will 
complete a Screening Visit which will include the following 
assessments: obtain written informed consent, obtain Screening 
number from IWRS , complete medical history ;if applicable, review
of anyhistorical liver biopsy  report obtained within 6 months of the 
date of the Screening Visit ; record all concomitant medications that 
the subject has taken within 30 day s prior to Screening; phy sical 
examination (PE) including vital signs, bod y weight, and height; 
dilated fundus exam or digita l fundus photograph y camera specified 
for non -dilated examinations (if required for subjects with type 2 
diabetes from medical history  or from Screening Hemoglobin 
A1c ≥6.5% onl y), laboratory assessments, serum pregnancy test 
(forfemales of childbearing potential); blood and ur ine collection for 
biomarkers, urine drug screen, [ADDRESS_747609]®, ELF™Test, 
FibroScan® ; documentation of all serious adverse events (SAEs) and 
adverse events (AE) related to Screening procedures; MRI -PDFF and 
MRE examinations. 
All subjects dete rmined eligible for the stud y based on the 
inclusion/exclusion criteria will then enroll into Pretreatment to begin 
Cycle 1 of the Kinetic Biomarkers. Subjects will consume deuterated 
water starting on Day -14 through Day  -8 to determine the effects of 
study drug(s) on kinetic parameters of de novo lipogenesis (DNL), 
fibrogenesis, and inflammation. The first dose of approximately  
45mL deuterated water will be administered under the supervision of 
investigative site personnel and monitored for at least 30 minutes 
after for an y side effects. Kinetic biomarker samples will be obtained 
on Day  -14, Day -11, Day  -7, and Day  1. 
Eligible subjects will be randomized on Day  1 to receive treatment 
for 24 -weeks with one of the following study  drugs: semaglutide; 
firsocostat (FIR; GS -0976) and semaglutide ; cilofexor (CILO; 
GS-9674) and semaglutide ; or firsocostat , cilofexor, and semaglutide . 
On-treatment study  assessments will include but are not limited to:
Symptom driven PE, vital signs, weight, chemistry , hematology , 
coagulation panel, and eGFR at Day 1 and at Weeks 1, 4, 8, 12, 
16, 20 and 24 
Fibro Scan®, MRI -PDFF, MRE, and FibroTest®at Weeks 12 and 
24
ELF™Test at Weeks 12 and 24
12-lead ECG at Week [ADDRESS_747610], Dose , 
and Mode of 
Administration : 
CONFIDENT IAL Final 
Amend ment2 
• Pregnancy testing (females of childbear ing potent ial only) at 
Day 1 and at Weeks 4, 8, 12, 16, 20 and 24 
I 
• Insulin and Lipi[INVESTIGATOR_569893] 1, Weeks 4, 8, 12 and 24 
• He moglobin Ale (HbAlc ) collection at Weeks 12 and 24 
• Si ngle PK sampling at Weeks 1, 4, 8 and 12 
I 
• Quality of Life (QoL ) quest io1ma ires: Chron ic Li ver Disease 
Questio1ma ire-Nona lchoho lic Fatty Liver Disease 
[CLDQ-NAFLD ], and EuroQo l five dimensions [EQ-5D ] at 
Day [ADDRESS_747611]. 
Name: [CONTACT_569962] (0.24 2.4mg) 
Dosage fonn: So lution for injection 
Rout e of admini stration: Subcutaneous 
Dosing instruct ions: Once week ly 
Delivery device: 3 mL PDS290 pre-fi lled pen-injector 
Name: [CONTACT_569963]: 30 mg or 100 mg tablet 
Rout e of admini stration: Oral 
Dosing instruct ions: Once daily 
Page 14 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 15 22 October 2019Name: [CONTACT_569964]: 20 mg tablet 
Route of administration: Oral 
Dosing instructions: Once daily
Dose, and Mode of 
Administration:Semaglutide: Dose escalation of semaglutide should take place 
during the first [ADDRESS_747612] aim 
to reach the recommended ta rget dose of semaglutide subcutane ous 
(s.c.) 2.4 mg once- weekly . Recommended dose escalation is as 
follows:
Weeks 1 through 4: 0.24 mg s.c. once weekl y 
Weeks 5 through 8: 0.5 mg s.c. once weekl y 
Weeks 9 through 12: 1 mg s.c. once weekl y 
Weeks 13 through 16: 1.7 mg s.c. once weekl y 
Weeks 17 thro ugh 24: 2.4 mg s.c. once weekl y.
Cilofexor:  One [ADDRESS_747613] to food
Firsocostat:  One [ADDRESS_747614] to food
Criteria for 
Evaluation:
Safety : Safety  will be assessed during the study  through the reporting of 
AEs, and b y clinical laboratory tests and vital sign assessments at 
various time points during the stud y. Concomitant medication usage 
will also be assessed throughout the stud y.
Pharmacokinetics: The PK of study  drug(s) and relevant metabolite(s) may  be evaluated, 
as applicable. PK samples may  also be used to measure 
protein
-binding of stud y drug(s) and/or its metabolites. Plasma 
concentrations of study  drug(s) will be provided in a listing. 
Statistical Methods:
Primary  
Endpoint:The primary  endpoint is the safet y and tolerability  of study  drug(s) in 
subjects with NASH.
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
I 
I 
I Final 
Amend ment2 
Efficacy Anal ysis: The biol ogica l activity of study drug(s) will be eva luated using 
radio logic endpo ints and biomarker variables. Because efficacy 
endpoints will be eva luated for exploratory purposes, fonna l 
statistical compar isons w ill not be made for these endpoint s. Instead, 
descr iptive statistics (n, mean, standard deviation [SD], median, 
CONFIDENT IAL P1 quart ile [Q 1 ], 3rd quart ile [Q3], minimum , and maximum) will be 
prov ided by [CONTACT_1570] . 
Page 16 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 17 22 October 2019Safety  Anal ysis: Safety  endpoints will be anal yzed by [CONTACT_569925] (n, mean, SD, median, Q1, Q3, minimum ,and 
maximum) for continuous values by  [CONTACT_1570].
Pharmacokinetic 
Analy sis:Plasma concentrations of study  drug(s) and 
relevant metabolite(s), as 
applicable, will be listed.
Kinetic Biomarker 
Analy sis:The kinetic biomarkers will be anal yzed to evaluate the 
pharmacod ynamic (PD) effects of stud y drug(s). The assessment will 
involve the anal ysis of DNL  values; specificall y,the change 
(absolute and relative) from baselin e between the post -dose and 
pre-dose deuterated water loading periods.
Sample Size: Due to the exploratory  nature of this study , the sample size was not 
determined b y any formal power calculation. The number of subjects 
in each treatment group was decided based on clinical experience 
with other similar proof of concept studies.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential do cuments.
Protocol GS -US-454-[ADDRESS_747615] aspartate aminotransferase
AUC area under the plasma/serum concentration versus time curve
AUC 2-12hr partial area under the plasma/serum concentration versus time curve from time 2 to 
time 12
AUC 24hr area under the plasma/serum concentration versus time curve from time zero to time 24
AUC inf area under the plasma/serum concentration versus time curve extrapolated to infinite 
time, calculated as AUC [ADDRESS_747616]+(Clast/z)
AUC last area under the plasma/serum concentration versus time curve from time zero to the last 
quantifiable concentrat ion
BAP Biomarker Analysis Plan
BCRP breast cancer resistance protein
BMI body mass index
BUN blood urea nitrogen
CAP controlled attenuation parameter
CFR Code of Federal Regulations
CI confidence interval
Clast last observed quantifiable plasma/serum concentration of the drug
CLDQ- NAFLD Chronic Liver Disease Questionnaire -Nonalcoholic Fatty Liver Disease
Cmax maximum observed plasma/serum concentration of drug
CP Child- Pugh
CPK creatine phosphokinase
CRN Clinical Research Network
CRO contract research organization 
CRP c-reactive protein
CsA single dose cyclosporine
CSR clinical study report
CT computerized tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrom e
CYP3A cytochrome P4503 A
CYP3A4 cytochrome P4503 A4
CYP7A1 cytochrome P450 7A1
DDI drug-drug interaction
DILI Drug Induced Liver Injury
DMC Data Monitoring Committee
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 19 22 October 2019DNA deoxyribonucleic acid
DNL de novo lipogenesis
DRSP Drospi[INVESTIGATOR_569894]™Enhanced Liver Fibrosis 
EQ-5D EuroQol five dimensions
F2 Moderate Fibrosis
F3 Bridging Fibrosis
F4 Com pensated Cirrhosis
FDA ([LOCATION_002]) Food and Drug Administration
FFD Fast food diet
FGF19 fibroblast growth factor [ADDRESS_747617] ratio
HRQoL Health Related Quality of Life
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council on Harmonisation of Technical Requirements for Registration of 
Pharm aceuticals for Human Use
ID Identification
IMP Investigational Medicinal Product
INR international normalized ratio
IRB institutional review board
IU international units
IUD intrauterine device
IV Intravenous
IWRS Interactive web response system
kg Kilogram
kPa Kilopascal
LDH lactate dehydrogenase
LDL low-density lipoprotein
LEAN Liraglutide Efficacy and Action in NASH
LLT lower-level term
MCV mean corpuscular volume
MDRD Modification of Diet in Renal Disease
MD multiple dose
MDZ Midazolam
MedDRA Medical Dictionary for Regulatory Activities
mg Milligram
min Minute
mL Milliliter
mm Millimeter
mmHg millimeter of Mercury
MRE magnetic resonance elastography
MRI -PDFF magnetic resonance imaging –proton density fat fraction
MRP2 multidrug resistance -associated protein 2
N Number
NAFLD nonalcoholic fatty liver disease
NaNO 2 sodium nitrite
NAS NAFLD Activity Score
NASH nonalcoholic steatohepatitis
NOAEL noobserved adverse event level
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 21 22 October 2019NTCP sodium -taurocholate cotransporting polypeptide
OATP organic anion -transporting polypeptide
OAD oral antidiabetic drug
OL Open -Label
PBC primary biliary cholangitis / probenecid
PD pharmacodynamic
PDGF platelet -derived growth factor
PE physical exam
P-gp Perm eability -glycoprotein
PI[INVESTIGATOR_569895] -reported outcomes
PSC primary sclerosing cholangitis
PT prothrombin time / Preferred Term
PTT partial thromboplastin time
PVE Pharm acovigilance & Epi[INVESTIGATOR_569896]
s.c. subcutaneous 
SD standard deviation
SD single dose
SEMA Semaglutide
SOC System  Organ Class
SOP standard operating procedure
SREBP -1c sterol regulatory element binding protein -1c
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TEAE treatment -emergent adverse event
T2D type 2 diabetes
TIMP -1 tissue inhibitor of metalloproteinase 1
Tmax time (observed time point) of C max
UGT UDP -glucuronosyltransferase
ULN upper limit of the normal range
US [LOCATION_002]
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 22 22 October 2019VAS Visual Analog Scale
VLDL very-large density lipoprotein
VORI Voriconazole
WBC white blood cell count
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 23 22 October [ZIP_CODE]. INTRODUCTION
1.1. Background
Chronic liver disease and the consequences of end- stage liver disease are increasing globall y 
despi[INVESTIGATOR_121994]. This is due to the emerging 
epi[INVESTIGATOR_569897], metabolic syndrome, and diabetes mellitus that are leading to an increased 
incidence of nonalcoholic fat ty liver disease (NAFLD). Nonalcoholic fatty liver disease is 
charac terized b y the excess accumulation of lipid droplets within the liver, also known as hepatic 
steatosis. Prevalence rates of NAFLD ran ges from 6% to 37% worldwide {Ong 2007 , Vernon 
2011} with a rec ent reported pooled global prevalence of 25% {Younossi 2016}.
Nonalcoholic steatohepatitis (NASH), an aggressive form of NAFL
D is present in approximately  
30% of NAFLD patients and is associated with increased liver -related mortality {Younossi 
2016}. Pathologically, NASH is characterized b y inflammation and hepatocellular ballooning, 
with or without fibrosis {Ong 2007 , Williams 2011 }. In the [LOCATION_002] (US) it has been 
estimated that 3% to 6% of the popula tion {Vernon 2011 },or the equivalent of ~[ADDRESS_747618] in these patients {Dietrich 2014 , Faramawi 
2008, Voulgari 2010 }. Given the absence of any  approved therapi[INVESTIGATOR_569898] -morbidities, NASH is expected to represent an increasi ngly large unmet 
medical need. 
As noted previousl y, NASH is primarily thought to occur as the result of the metabolic 
syndrome: the impact of obesit y, insulin resistance, and dy slipi[INVESTIGATOR_035]. Fatty  liver, or simple 
steatosis is not sufficient to cause liver injur y. Rather, it is the presence of inflammation and 
hepatocellular injury on the background of steatosis that defines NASH and may  result in t he 
progression to cirrhosis and its complications. The “2
-hit” hy pothesis of NASH suggests that in 
the setting of steatosis and metabolic d ysfunction, increased oxidative stress and the generation 
of reactive ox ygen species (ROS) likely mediate the inflammatory changes in the liver 
(steatohepatitis) that may lead to progressive fibrosis {Dowman 2010, Koek 2011, Sumida 
2013}. The major pathway s in NASH disease progression include those involved in metabolic 
dysfunction in the hepatocy te, and activation of hepatic stellate cells and macrophages leading to 
progressive infl ammation and liver fibrosis. Advanced fibrosis and cirrhosis are characterized by
[CONTACT_569926]. Additionally , evidence 
suggests that lipotoxic intermediates of fatt y acids likely contribute to the etiology  of NASH 
{Neuschwander -Tetri 2010 }.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 24 22 October 2019Over time, NASH may result in progressive liver fibrosis, ultimately leading to cirrhosis in 
10-20% of affected patients. Advanced fibrosis (bridging fibrosis or cirrhosis) is associated with 
increased morbidity a
ndmortalit y {Ekstedt 2015, Yeh 2014 }. Cirrhosis increases the risk of
hepatocellular carcinoma (HCC) and other complications of en d-stage liver disease, including 
jaundice, fluid retention (edema and ascites), portal hypertension and variceal bleeding, impaired 
coagulation and hepatic encephalopath y
. Decompensated liver disease, as defined b y the 
development of one of the above complications, has a high mortality and the on
ly known 
effective treatment is liver transplantation. With the increasing prevalence of obesity and 
obesity -related diseases, NASH is expected to become the leading indication for liver 
transplantation and the leading etiology  of HCC among liver transplant recipi[INVESTIGATOR_121997] 
{Afzali 2012, Wong 2014}.
1.2. General Information for Semaglutide
1.2.1. General Information
Semaglutide is a glucagon -
like peptide- [ADDRESS_747619] (GL P-1 RA) currently  in development 
for weight management and non- alcoholic steatohepatitis. Semaglutide at once weekl y doses of 
0.[ADDRESS_747620] to diet and exercise for the management of 
Type 2 diabetes under the trade name, Ozempic®. 
Semaglutide is based on the same technology  as used for liraglutide (Victoza®,Saxenda®), with 
fatty acid acy lation and albumin binding as the protraction principle, and with maintained high 
homology  to human GLP -1.  Semaglutide has been modified resulting in a longer half -life 
suitable for once weekl y dosing and is stabilized again st degr adation by  [CONTACT_161220] -4 enzy me. The 
extended half -life of the semaglutide molecule is primarily  obtained by [CONTACT_569927], which is facilitated by
 a large fatt y acid -derived chemical moiet y. 
Please refer to the Investig ator’s Brochure (IB) for additional information on semaglutide , 
including:
In vitro activity
Nonclinical in vivo efficacy  studies
Nonclinical pharmacokinetics and in vitro metabolism
Nonclinical pharmacology  and toxicology
Clinical pharmacokinetics and phar macody namics
Safety  in healthy  subjects, subjects with obesity  and subjects with ty pe 2 diabetes ( T2D)
Protocol GS -US-454-[ADDRESS_747621] shown that semaglutide lowers blood glucose, food intake and 
body  weight in animal models of diabetes and obesity . Furthermore, semaglutide attenuated the
development of atherosclerosis and had an anti- inflammatory  action in the cardiovascular (CV)
system. Semaglutide exerts its actions through the GL P-[ADDRESS_747622] shown that the GL P-1 receptor is not expr essed in normal human thy roid C -cells. 
Accordingl y, the human relevance of rodent C- cell tumors is considered to be low, but cannot be 
completely  excluded. 
Semaglutide adversel y affected embry ofetal development in the rat by  a GLP -1 receptor
mediated impaired function of the inverted yolk sac placenta during a period of gestation when 
the ra t embry o is entirely dependent on the yolk sac placenta for its nutrient supply . Due to 
species differences in yolk sac anatom y and function, and due to the lack of GL P-1 receptor 
expression in cy nomolgus monkey  yolk sac, this mechanism is considered unlik ely to be of 
relevance to humans. Involvement of additional mechanisms cannot be excluded. In rabbits and 
monkey s, increased number of pregnancy  losses and slightly  increased incidences of foetal 
abnormalities, which did not resemble the findings in rats, were observed. These findings might 
be incidental or related to the markedl y reduced maternal bod y weight; however, relevance to 
humans cannot be completely  excluded for these findings.
Refer to the Semaglutide IB for additional details.
1.2.3. Clinical Trials with Semaglutide 
As part of the T2D development program, semaglutide once weekl y was evaluated in 9 
Phase 
3a/b trials (including a 2 -year cardiovascular outcomes trial [CVOT]). Across all Phase 3a/b 
efficacy  trials, both semaglutide 0.5 mg and 1.0 mg were superior in lowering gl ycosylated 
hemoglobin (HbA1c) and body  weight as compared with placebo (both as monotherapy  and in 
combination with insulin) or compared with the respective marketed comparators. CV safety  of 
semaglutide was established in the CVOT with an estimated hazard ratio (HR) for semaglutide 
vs. placebo of 0.74 [0.58; 0.95] 95%CI  corresponding to a reduced risk of major adverse 
cardiovascular events (MACE) by  26% vs. placebo.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 26 22 October 2019The PK and PD properties of semaglutide s.c. administered once weekl y was investigated as part 
of the T2D development program including a total of 16 clinical pharmacology  trials. 
Semaglutide has PK properties compatible with once-weekl y administration with a median time 
to maximum concentration (tmax) of 1 -3 day s and an elimination half -life (t½) of approximately  
1 week. The exposure of semaglutide in subjects with various degrees of impaired renal function 
and with various degrees of impaired hepatic function was similar to the exposure in subjects 
with normal renal function and normal hepatic function, respectivel y. No clinically  relevant 
drug-drug interactions (DDI s) were observed between semaglutide and any  of the orall y 
administered compounds tested (in cluding metformin, warfarin, digoxin, atorvastatin and oral 
contraceptive combination drugs) and thus, no dose adjustments of the orally  administered drugs 
are required. Semaglutide circulates in plasma, highl y bound to plasma protein. Prior to 
excretion, semaglutide is metabolized and excreted in urine and feces , with only  3% of the 
administered dose excreted as intact semaglutide.
For the evaluation of semaglutide in weight loss, Novo Nordisk A/S has conducted one phase [ADDRESS_747623] weight loss (estimated mean change in body  weight - 13.84%) 
observed with the highest semaglutide dose tested (0.4 mg, once dail y). Weight loss was
accompanied b y consistent improvements in weight- related comorbidities, such as CV risk 
factors as well as in patient- reported outcomes (PRO). No unexpected safety  findings were 
identified and the tolerability  and safety  profile was overall consistent wit h previous findings in 
the semaglutide s.c. development program for T2D and the GLP -[ADDRESS_747624] 
frequentl y reported AEs were gastrointestinal (GI) disorders (mainl y nausea).
Semaglutide did not increase the risk of severe or blood gluco se (BG) confirmed sy mptomatic 
hypoglycemia when used as monotherapy or in combination with oral antidiabetic drugs (OADs) 
(excluding sulphony lurea), and onl y slightl y increased the risk when used in combination with 
insulin and with sulphonylurea.
Allergic reactions and injection site reactions were generall y infrequent, non- serious and of mild 
or moderate severit y and reported b y a similar proportion of subjects on semaglutide and placebo 
and comparator products (allergic reactions: 4 6%) and (injection site reactions ~1%).
Data from the CVOT in T2D showed that semaglutide treatment was associated with an 
increased risk of diabetic retinopathy  complications in subjects with pre -existing diabetic 
retinopathy , albeit at low risk. This finding is believed to be attributable to t he rapid initial 
improvement in BG levels with semaglutide, consistent with the earl y worsening phenomenon 
described with insulins. Patients with a history  of diabetic retinopath y should be monitored for 
worsening and treated according to clinical guidelin es. 
No causal association between semaglutide and any  type of neoplasms has been seen in the 
clinical development program. The incidence of pancreatic cancer and breast neoplasms was low 
and appeared not to be different from placebo or other comparators.
Protocol GS -US-454-[ADDRESS_747625] of the Farnesoid X Receptor (FXR) whose activity in 
intestinal epi[INVESTIGATOR_121998] 19 ( FGF19). FGF19 is 
an endocrine peptide which drives a signaling cascade to decrease lipogenesis, gluconeogenesis, 
hepatic trigly ceride accumulation, and bile acid sy nthesis. Thus cilofexor , by [CONTACT_569928], is 
expected to improve NASH. Please refer to the Investigator’s Brochure (IB) for additional 
information on cilofexor , including:
In vitro FXR agonism
Nonclinical in vivo efficacy  studies
Nonclinical pharmacokinetics and in vitro metabolism
Nonclinical pharmacology  and toxicology
1.3.2.
Nonclinical Pharmacology and Toxicology
In vivo pharmacology  studies have demonstrated that c ilofexor preferentially  activates intestinal 
FXR and reduces liver fibrosis. I n cynomolgus monkey s, there was an increase in circulating 
FGF19 levels after oral dosing of cilofexor but not after IV dosing despi[INVESTIGATOR_569899]. These data suggest that intestinal FXR agonism by [CONTACT_569929]19 production, whereas low s ystemic free drug concentrations limit effects following IV 
administration of 
cilofexor . In addition, the oral administration of c ilofexor to monkey s directl y 
activated intestinal FXR, as measured b y the expression of FXR -target genes in the ileum 
(FGF19, OSTα, and OSTβ mRNA). In a mouse model of NASH induced by  a diet enriched in 
fat, cholesterol and sug ar, cilofexor reduced hepatic steatosis and normalized bile acid levels in 
plasma. In a choline -deficient high fat diet /NaNO2 rat model of liver fibrosis that utilizes 
“2hits” to mimic the metabolic and oxidative stress components of NASH in humans, cilofexor
dose dependently  reduced both biochemical and histological measures of liver fibrosis. Overall, 
the results from these pharmacology studies demonstrate that c ilofexor is a potent and selective 
agonist of intestinal FXR with the potential to benefit N ASH patients b y inducing FGF19 
production.
The oral bioavailability  of cilofexor was low in the nonclinical species. cilofexor was extensively  
bound to plasma proteins in all species. In mice, [14C] cilofexor -derived radioactivity  was 
distributed to most of the tissues, with the highest maximum concentrations of radioactivity  
determined in organs of absorption and excretion. No quantifiable radioactivity  was detected in 
brain, suggesting [ 14C] c ilofexor -derived radioactivity  did not cross the blood: brain barrier. The 
primary  cilofexor metabolic pathway s in pooled cry opreserved hepatocy tes were observed to be 
oxidative. Comparison of metabolism in hepatocy tes from mice, rats, dogs, monkey s, and 
humans did not identify  any metabolites unique to humans. The p
rimary  metabolic pathway s of 
[14C] Cilofexor in vivo were oxidation and O-dealky lation in mice, rats, and monkey s; 
glutathione conjugation was observed in mice and rats; additionally , dechlorination was observed 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 28 22 October 2019in mice. Fecal elimination was a predominant route of elimination of [ 14C] cilofexor -derived 
radioactivity  in both mice and monkey s.
Based on nonclinical assay s, cilofexor has the potential to affect hepatic/intestinal uptake of 
organic anion
-transporting pol ypeptide (OATP )substrates or metabolism of CYP2C8, CYP2C9, 
or CYP3A4 substrates when its concentrations are sufficiently  high. However, low solubility , 
high protein binding (> 99.98%), and low s ystemic levels reduce the potential for cilofexor to 
cause drug
-drug interactions (DDIs) via inhibitio n of metabolic enzy mes and transporters. 
GS-716070, an inactive metabolite of cilofexor , was found to inhibit human OATP1B1, 
OATP1B3, and OATP2B1 with IC [ADDRESS_747626] cancer resistance protein 
(BCRP ), as well as the uptake transporters OATP1B1, OATP1B3, OATP2B1, and sodium -
taurocholate cotransporting pol ypeptide ( NTCP) . Inhibitors or genetic pol ymorphisms affecting 
the activity of these transporters may  affect cilofexor intestinal absorption and hepatic uptake.
Cilofexor and GS -716070 did not activate nuclear hormone receptors associated with the 
potential for induction of human drug -metabolizing enz ymes and transporters (eg, PXR, CAR, 
AhR) in cell -based reporter assay s. Thus, the liability  of cilofexor and GS -716070 to cause DDIs 
through proteins regulated by  [CONTACT_569930].
Based on nonclinical assay s, GS -1056756 (the R -enantiomer of M13), an inactive, major 
circulating metabolite of cilofexor has shown low potential to inhibit CYP enzy mes (IC 50 values 
of 3.49 for CYP2C8 and >25 uM for CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6) and 
UDP -glucuronos yltransferase (UGT )(IC 50 value of 13.9 for 
UGT1A1) in vivo. GS -1056756 did 
not inhibit P -gp, BCRP, OCT2, MATE1, MATE2K, and showed low probability  to be clinicall y 
relevant inhibitor of OAT1, OCT1, OATP1B1, OATP1B3 or OATP2B1. No clinical DDI 
liability  of GS -1056756 on enzy mes and transporters was predicted from in vitro 
characterizations.
GS-1056756 has been identified in nonclinical assay s as a substrate of OATP1B1/1B3. In vitro,
GS-1056756 is formed by  [CONTACT_569931]3A4 and CYP2C8 with additional 
conversion to enantiomers by  [CONTACT_569932] (eg, ALDH), and is subsequently  metabolized by  
[CONTACT_097]3A and CYP2C8 and UGTs. Together with available clinical data described in
Section 1.3.3, the potential clinical DDI liability  of GS -1056756 is low.
The nonclinical toxicity  profile of 
cilofexor has been assessed in mice and cy nomolgus monkey s 
administered cilofexor orally  for up to 26 and 39 weeks, respectivel y. Findings attributed to 
cilofexor administration were primarily  related to the liver (increases in alkaline phosphatase, 
decreases in serum bile acids, cholesterol and trigly cerides, increases in liver weight and 
hepatocellular h ypertrophy ) and were likel y related to the pharmacology of cilofexor . These 
findings were minimal to mild, non- adverse, and reversible after discontinuation of treatment. 
The no observed adverse event levels ( NOAELs )after 26 and 39 weeks of dosing in mice and 
monkey s, respectively , were associated with exposures (AUC 24h) that were 22- and 32- fold 
higher in mice and monkey s, respectively , than the observed exposure in humans administered 
[ADDRESS_747627] 2018, 4 Phase 1 clinical studies are complete, 2 Phase 1 s tudies are ongoing 
(GS-US-402- 3885 and GS -US- 402-4287), 1 Phase 2 study  in subjects with NASH is complete 
(GS-US-402- 1852) and 4 Phase 2 studies in subjects with NASH (GS -US- 384-3914, 
GS-US-454- 4378), Primary  Biliary  Cholangitis (PBC) (GS -US- 427-4024), and
PSC (GS-US-
428-4025) are ongoing. These Phase 1 and 2 studies are described in the IB. A 
brief summary  of relevant PK results supporting this protocol is presented below, including 
preliminary  results that are not included in the IB from ongoing study  GS-US-
402-3885 and 
GS-US-
428-4025. Preliminary  clinical PK data for the newl y identified major circulating 
cilofexor metabolite GS -1056756 (the R -enantiomer of M13) is described in Sections [IP_ADDRESS]. 
Briefl y, GS -1056756 exhibits a plasma half -life of approximately  175 h. Preliminary  steady -state 
plasma concentrations of GS
-1056756 in PSC patients administered 100 mg cilofexor are as 
expected based on the preliminary  single dose PK data for GS -1056756 from the ADME study  
(GS-US-402- 4287). Additionally , plasma exposures of GS -1056756 are minimally  altered in 
subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic 
function. 
These data, taken together with the adequate safety  margins from nonclinical safet y 
studies and the nonclinical understanding of the metabolic formation (CYP3A and CYP2C8) and 
clearance (CYP3A, CYP2C8, and UGTs) mechanisms of GS -1056756 support the concomi tant 
medication restrictions in Section 5.3.
1.3.4. A Phase 1, Open -Label, Parallel- Group, Adaptive, Single -Dose Study to 
Evaluate the Pharmacokinetics and P harmacodynamics of Cilofexor in 
Subjects with Normal and Impaired Hepatic Function 
(Study GS-US-402-3885)
Study  GS-US-402-3885 is an ongoing Phase 1, open -label, parallel -group, single dose stud y 
evaluating the safet y, tolerability, PK, and PD of cilofexor in subjects with normal hepatic 
function and mild, moderate, or severe hepatic impairment. Up to 60 subjects are planned for 
enrollment in 1 of 3 hepatic impairment cohorts: Cohort 1 (mild hepatic impairment, CP A), 
Cohort 2 (moderate hepatic impairment, CP B), and Cohort 3 (severe hepatic impairment, CP C). 
Within each cohort, each subject with impaired hepatic function (N 10 per cohort) will be 
matched for age (± 10years), sex, race, and bod y mass index (BMI : ± 15%) with a control 
subject with normal hepatic function (N 10 per cohort). Data from health y subjects may  be used 
in >[ADDRESS_747628] with hepatic function in 
>1cohort. All subjects in Cohorts 1 and 2 will receive a single oral dose of cilofexor 30mgin 
the fed state on Day 1 with PD collected on Day -1 and Day 1. All subjects in Cohort 3 will 
receive a single oral dose of cilofexor 10mg in the fed state on Day 1 with PD collected on 
Day -1 and Day 1. 
[IP_ADDRESS]. Subject Disposition
As of [ADDRESS_747629] prematurel y discontinued study  treatment due to quality  issues at the site 
that justified a suspension in dosing at the site. No subjects prematurely  discontinued due to an 
adverse event (AE), withdrew consent, or were lost to follow -up. 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 30 22 October [ZIP_CODE].3.4.2. Preliminary  Safet y Results 
Overall, 8.8% of subjects had a treatment-emergent adverse event (TEAE) of Grade 1 or 2. There 
was 1 serious adverse event (SAE ) of gastrointestinal bleed that was not related to study  drug. 
This subject had a history  of esophageal variceal bleeding and experienced bleeding requiring 
hospi[INVESTIGATOR_569900]. There were no pregnancies or deaths. 
In the mild hepatic impairment cohort, there were 2 subjects (20%) that had Grade 3 lab 
abnormalities of elevated gamma glutam yl transferase (GGT) and low platelets. The Grade [ADDRESS_747630]’s baseline. There was [ADDRESS_747631] (10%) 
who had Grade 3 lab abnormalities in total cholesterol and LDL cholesterol (LDL -C), which 
were stable from their baseline. In the moderate hepatic impairment cohort, 2 subjects (20%) had 
Grade [ADDRESS_747632]’s baseline. 
One subject, who had a SAE of gastrointestinal bleeding in the moderate hepatic impairment 
cohort (described above), had a Grade 4 lab a bnormality  of low hemoglobin. I n the severe 
hepatic impairment cohort, 4 subjects (40%) had greater than or equal to Grade [ADDRESS_747633] had occult blood in 
urine.
[IP_ADDRESS]. Preliminary  PK Results
Preliminary  PK results are presented below and in Table 1-1:
Cohort
1 (mild hepatic impairment; CP A): cilofexor exposure (AUC infand C max) was higher 
in subjects with mild hepatic impairment (approximately  76% and 57%, respectively ) as 
compared to subjects with normal hepatic function. I n subjects with mild hepatic impai rment, 
exposure (AUC infand C max) of the metabolite GS -716070 was similarly  higher 
(approximately  64% and 25%, respectively ). Overall exposure for GS -1056756 was modestly  
higher (AUC infwas increased 28% and C maxincreased 7%) in subjects with mild hepatic
impairment compared with subjects with normal hepatic function. cilofexor and GS -
716070 
had minor changes in plasma protein binding (unbound fraction [f u] increased ~30%). CILO 
is a hepatic OATP substrate and OATP expression/activity  may  be altered in pat ients with 
cirrhosis. Thus, altered OATP expression/activity  may  contribute to the observed higher 
systemic exposure of cilofexor . At a dose of 100 mg QD in subjects with mild hepatic 
impairment, exposure margins relative to preclinical NOAEL exposures for both parent and 
metabolites are expected to remain adequate.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 31 22 October 2019Cohort 2 (moderate hepatic impairment; CP B): CILO exposure (AUC infand C max) was 
higher in subjects with moderate hepatic impairment (approximately  2.3- and 1.6 -fold, 
respectivel y) as compared 
to subjects with normal hepatic function. Exposure (AUC inf) of the 
metabolite GS -716070 was also higher (approximately 1.6 -fold) with minimal change in 
Cmax. GS-1056756 AUC infwas increased 16% and C maxwas 30% lower in subjects with 
moderate hepatic impairment compared with subjects with normal hepatic function. Plasma 
unbound fraction (f u) of cilofexor and GS -716070 was increased ~96% and ~85%, 
respectivel y, in moderate hepatic impairment, leading to a > 4-fold and > 3- fold increase in 
free drug exposures of parent and metabolites, respectivel y. 
Cohort 3 (severe hepatic impairment; CP C): cilofexor exposure (AUC infand C max) was 
higher in subjects with severe hepatic impairment (approximately  6.2- and 2.5-fold, 
respectivel y) as compared to subjects with normal hepatic function. Exposure (AUC inf) of the 
metabolite GS -716070 was also higher (approximately 3 -fold) with C max reduced by 33%. 
GS-1056756 AUC infwas approximately  2.6-fold higher and C maxapprox imately  39% lower 
in subjects with severe hepatic impairment compared with subjects with normal hepatic 
function. 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 32 22 October 2019Table 1-1. GS-US- 402-3885: Preliminary Cilofexor , GS-716070, and GS - 1056756 
PK Parameters Foll owing a Single Dose of Cilofexor 30 mg or 10 mg 
in Subjects with Hepatic Impairment or Normal Hepatic Function
Cohort AnalyteMean (%CV) PK 
Param eterMatched 
Healthy 
Control (N=10)Hepatic 
Impairment 
(N=10)%GMR
(90% CI)
1
(Mild HI, 
CILO 30 mg)CilofexorAUC inf(hr.ng/mL)3030 
(40.5)5410 
(40.2)176
(127, 253)
AUC last(hr.ng/mL)2970 
(41.4)5380 
(40.4)178
(128, 247)
Cmax(ng/mL)604 
(45.6)994 
(53.7)157
(108, 229)
GS-716070AUC inf(hr.ng/mL)1440 
(49.7)2330 
(44.8)164
(104, 259)
AUC last(hr.ng/mL)1400 
(51.1)2300 
(44.8)169
(115, 247)
Cmax(ng/mL)179 
(42.6)234 
(50.8)125
(85.0, 188)
GS-
1056756AUC inf(hr.ng/mL)2040 
(57.7)2850 
(69.5)128
(80.1, 204)
AUC last(hr.ng/mL)850 
(45.6)1030 
(70.0)109
(73.0, 163)
Cmax(ng/mL)13.0 
(44.4)15.5 
(70.1)107
(70.4 -161)
2
(Moderate HI, 
CILO 30 mg)CilofexorAUC inf(hr.ng/mL)2810 
(30.3)8280 
(91.4)230 
(163, 324)
AUC last(hr.ng/mL)2460 
(30.9)8220 
(91.1)249 
(169, 367)
Cmax(ng/mL)496 
(40.2)909 
(52.5)164 
(115, 233)
GS-716070AUC inf(hr.ng/mL)1380 
(47.7)3160 
(81.8)163 
(95.1, 280)
AUC last(hr.ng/mL)1340 
(48.8)3090 
(80.9)197 
(117, 329)
Cmax(ng/mL)168 
(51.6)181 
(61.5)89.5 
(54.3, 147)
GS-
1056756AUC inf(hr.ng/mL)1620 
(41.6)1900 
(41.2)116
(83.5 -161)
AUC last(hr.ng/mL)734 
(40.7)586 
(34)79.4
(58.3, 108)
Cmax(ng/mL)11.6 
(39.7)8.25 
(37.6)70.0
(50.2, 97.6)
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 33 22 October 2019Cohort AnalyteMean (%CV) PK 
Param eterMatched 
Healthy 
Control (N=10)Hepatic 
Impairment 
(N=10)%GMR
(90% CI)
3
(Severe HI, 
CILO 10 mg)CilofexorAUC inf(hr.ng/mL)989 
(36.4)6710 
(60.3)623
(430, 905)
AUC last(hr.ng/mL)963 
(37.2) 6535
(58.0) 631
(437, 913)
Cmax(ng/mL)182 
(47.5)427 
(32.0)254
(177, 365)
GS-716070AUC inf(hr.ng/mL)2450 
(77.5)688 
(50.1)303
(173, 528)
AUC last(hr.ng/mL)2070 
(71.2) 653 
(52.9)280
(166, 473)
Cmax(ng/mL)47.9 
(45.6)77.2 
(55.7)67.0
(44.3 -101)
GS-
1056756AUC inf(hr.ng/mL)520 
(38.8)3360 
(181)262
(118, 581)
AUC last(hr.ng/mL)241 
(39.2)181 
(45.8)73
(51.0, 104)
Cmax(ng/mL)3.67 
(37.0)2.35 
(50.2)60.7
(41.9, 88.0)
Data reported to 3 significant figures
Preliminary  PD results for Cohort 1 are also available for change from baseline (Day -1) in 
plasma FGF19 and serum 7 -alpha -hydroxy-4-cholesten - 3 -one (C4) levels following a single 
30-mg dose of cilofexor . Changes in FGF19 and C4 followi ng a single dose of cilofexor were 
similar in the mild hepatic impairment subjects as compared to the health y matched controls 
as indicated b y the PD parameter ratios (mild hepatic impairment/healthy) for C maxand 
AUC 212hrfor FGF19 (1.1 and 1.1, respecti vely) and for C minand AUC 212hrfor C4 (0.82 and 
0.87, respectivel y) that were not significantl y different from 1.
Based on the preliminary PK and PD data from this study  as well as the overall safet y profile 
of cilofexor , dose adjustments are not considered necessary  in subjects with mild hepatic 
impairment.
For further information on cilofexor , refer to the current IB.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 34 22 October [ZIP_CODE].4. General Information for Firsocostat
1.4.1. Firsocostat
Firsocostat is a small molecule allosteric inhibitor that acts at the protein -protein homodimer 
interface of acet yl coenzy me A (acet yl-CoA) carboxy lases (ACC) ACC1 and ACC2 to prevent 
dimerization. ACC1 and ACC2 are important regulators of fatt y acid metabolism. ACC1 
catal yzes the first step of de novo lipogenesis (DNL) b y converting a cetyl-CoA to malony l-CoA 
while ACC2 regulates the entry  of fatty  acids into the mitochondria where beta oxidation can 
occur. Therefore, inhibition of ACC1 and ACC2 will reduce DNL and increase fatt y acid beta 
oxidation. Firsocostat is being developed for t he treatment of nonalcoholic steatohepatitis 
(NASH) under IND 124915.
For further information on firsocostat , refer to the current IB.
1.4.2. Nonclinical Pharmacology
Firsocostat has been characterized in several biochemical and cellular assays to enhance the 
understanding of the mechanism of action and has been well characterized in vivo in several 
mechanistic models to demonstrate target engagement and in animal disease models to 
demonstrate specific activity  on endpoints relevant to metabolic disease. Moreover, extensive 
safet y pharmacology and receptor screening studies have been conducted.
The results of these pharmacod ynamic (PD) studies indicate that firsosostat 
can reduce the DNL, 
hepatic steatosis, insulin resistance, and fibrosis produced in nonclinical models of metabolic 
disease and fibrosis without affecting food consumption or markers of liver function.
As described in the IB, GS -834356, a liver -targeted ACC inhibitor and analogue of firsocostat , 
reduced steatosis in a murine model of NASH induced b y a diet enriched in fat, cholesterol, and 
fructose (Fast food diet, FFD). ACC inhibition by  [CONTACT_10827]-[ADDRESS_747634], and markers of hepatic 
fibrosis, but also dose -depende ntly increased plasma trigl ycerides in this model. GS -834356 also 
decreased hepatic trigl ycerides and increased plasma trigl ycerides in a rat high fat, high sucrose 
model of hepatic steatosis. These findings are consistent with a recent report that pharmac ologic 
or genetic inhibition of ACC in the liver decreases hepatic trigly ceride levels and increases 
plasma trigl yceride levels {Goedeke 2018 , Hertz 1995 , Kim 2017}.
In high fat, high sucrose fed rats, GS -
834356- induced increased plasma trigly cerides were found 
to be due to increased very -large density  lipoprotein (VLDL) secretion and decreased clearance 
of trigl yceride -rich VLDL and chy lomicrons2. The increase in plasma trigly cerides b y ACC 
inhibition was accompanied by [CONTACT_569933]3 protein, which inhibits lipoprotein 
lipase activity  and suppresses VLDL and chy lomicron clearance. ApoC3 transcription in 
hepatocy tes is repressed by  [CONTACT_569934] . Evaluation of gene 
transcription profiles of FFD -fed mice treated with the ACC inhibitor GS -834356 revealed a 
reduction in PPAR target gene signatures2.These findings suggest that ACC inhibition in the 
liver leads to a reduction in hepatic PPAR activity  and associated increases in VL DL and 
ApoC3 production, and reduced VLDL/ch ylomicron clearance. Indeed, the combination of ACC 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 35 22 October 2019inhibition with PPARα agonism using fenofibrate blocked the ACC-induced plasma TG 
increases in the mouse NASH model. I mportantly , the combination of the ACC inhibitor and 
fenofibrate caused a similar reduction in hepatic trigl ycerides compared to ACC inhibitor 
treatment alone. In addition, the combination caused a greater increase in plasma ketone bodies 
(a marker of fatty  acid beta -oxidation) and a greater reduction of hepatic cholesterol levels 
relative to ACC inhibition alone2. These findings demonstrate that the addition of fenofibrate 
overcomes trigl yceride elevations induced b y AC C inhibition and further increases fatt y acid 
oxidation and cholesterol metabolism.
In total, these studies confirm the potential for firsocostat to impact important metabolic 
endpoints associated with NASH, and for the addition of PPAR agonists to reverse increases in 
plasma trigly cerides.
Please refer to the firsocostat IB for additional details.
1.4.3. Nonclinical Toxicology
The nonclinical toxicologic profile of firsocostat has been well characterized in single -and 
repeat -dose toxicity  studies up to 39 weeks in duration and in genetic toxicity ,embry o-fetal 
developmental toxicity , and local tolerance studies.
Firsocostat was well tolerated up to 13 weeks in the mouse, 26 weeks in the rat, and 39 weeks in 
the dog. The primary  target organ toxicity  was the presence of cataracts and/or lens degener ation 
in the mouse and dog after [ADDRESS_747635] dose (5 mg/kg/day ) had lens degeneration, none of the male mice at 
the same dose, whereas they  did at [ADDRESS_747636] that ey e findings at lower exposures in the 
2-week stud y ma y not be clinically relevant. In the dog, lens degeneration/cataracts were 
firstobserved after 13 weeks of firsocostat adminis
tration. While lens degeneration/cataracts 
were also observed in the chronic dog stud y, these findings occurred at exposures > [ADDRESS_747637] 48times 
the clinical exposure at 20 mg. firsocostat was not genotoxic and there was no embry o-fetal 
developmental toxicity  at exposures approximately  50 times the clinical exposure. Firsocostat 
was considered non -corrosive and does not require classification as an ey e irritant.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 36 22 October 2019Based on the s ystemic concentrations of firsocostat measured in the repeat -dose toxicity  studies 
in mice, rat and dog at the projected clinicall y efficacious AUC (88 ng•h/mL), the margins of 
exposure at the NOAELs are 8, 206 and 48 in the mouse, rat and dog, respectively . Thus, data 
from the nonclinical stu dies support the continued clinical evaluation of 20 mg firsocostat .
Please refer to the firsocostat IB for additional details.
1.4.4. Nonclinical Pharmacokinetics
Firsocostat is highl y protein bound in plasma, and the volume of distribution of firsocostat across
nonclinical species is greater than total bod y water (0.7 L /kg), suggesting that firsocostat is well 
distributed. A significant fraction of the absorbed parent compound is extracted by  [CONTACT_569935] (ie, the liver).
The metabolism of firsocostat has been evaluated in in vitro incubations of rat, dog, C ynomolgus 
monkey , and human hepatocy tes. No metabolites unique to the human were detected. In vivo 
metabolite identification studies in Sprague -Dawley  rat and Beagle dog have demonstrated that 
the primary  metabolite of firsocostat is the glucuronide conjugate, NDI -011535, renamed as 
GS-834773.
Neither firsocostat nor GS -834773 inhibits the cy tochrome P450 (CYP) enzy mes involved in 
drug metabolism. Firsocostat is not an inducer of CYP1A2 or CYP2B6 isozy mes and is a mild 
inducer of CYP3A4 in human hepatocy tes in vitro.
A single nonclinical study to evaluate elimination of firsocostat and the metabolite GS
-[ADDRESS_747638] cannulated Sprague- Dawley  rats to profile concentrations over time 
in plasma, urine, and bile. Overall, the pharmacokinetic (PK) profile in plasma and bile indicate 
that firsocostat is rapi[INVESTIGATOR_2478] y cleared from the plasma compartment, and the primary  route of 
elimination is via the bile.
Please refer to the firsocostat IB for additional details.
1.4.5. Clinical Trials of Firsocostat
As of [ADDRESS_747639] been completed or are 
ongoing. 
Information about completed and ongoing clinical studi es can be found in the firsocostat IB.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 37 22 October [ZIP_CODE].4.5.1. Study  GS-US-426- 4074: A Phase 1 Study  to Evaluate Transporter and 
Cytochrome (CYP) 450
-Mediated Drug -Drug Interactions between Firsocostat
and Probe Drugs
Study  GS-US-426- 4074 is an ongoing, open -label, multiple -cohort study  designed to evaluate 
transporter and CYP -mediated drug -
drug interactions (DDIs) between firsocostat (10, 20, or 
50mg) and various probe drugs in health y subjects. The effect of an organ ic anion -transporting 
polypeptide (OATP)1B1/1B3 inhibitor on the PK/PD relationships of firsocostat ,as assessed b y 
changes in fractional DNL, will also be evaluated.
[IP_ADDRESS].1. Subject Disposition
As of 1 November 2017, a total of 90 subjects were dosed; [ADDRESS_747640].
[IP_ADDRESS].2. Preliminary  Safet y Results
Forty-eight out of 90 subjects (53.3%) experienced an AE. Of these subjects, 10 subjects 
experienced AE(s) that were deemed related to the study  drug. The most common AE was 
headache (20%). All of these AEs were Grade [ADDRESS_747641] discontinued the study  due 
to an AE.
Fourteen subjects (15.6%) experienced a Grade 3 lab abnormalit y. Thirteen of these subjects had 
asymptomatic hematuria (3+) on their urine dipstick, and all were menstruating females. 
One subject had a Grade 3 asy mptomatic elevation of their total and low-density  lipoprotein 
(LDL) cholesterol, and one subject had a transient Grade 3 decrease in hemoglobin. There were 
no Grade 4 lab abnormalities.
[IP_ADDRESS].3. Preliminary  PK Results
Preliminary  PK results from the following cohorts are presented below and in Table 1-2.
Cohort 1: I mpact of OATP/multidrug resistance
-associated protein 2 (MRP2)/permeabilit y 
glycoprotein (P -gp) inhibition (single dose cy closporine [CsA ] 600 mg: CsA) or OATP1B1/1B3 
inhibition (single dose rifampin [RIF] 600 mg: RIF) on single dose of firsocostat 20 mg (N 28). 
Single doses of CsA and RIF significantl y increased firsocostat exposure (21.2- and 18.4- fold, 
respectivel y) and resulted in even greater increases in GS -834773 exposures (64.5- and 
55.4- fold, respectivel y). These data indicate firsocostat is a sensitive substrate of hepatic OATP 
with intestinal P -gp play ing a minimal role in firsocostat absorption as seen by  a smaller increase 
in firsocosta t Cmaxby [CONTACT_569936].
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 38 22 October 2019Cohort 2: I mpact of pan-UGT inhibition (probenecid [PBC] 500 mg: PBC) and CYP3A4 
inhibition (voriconazole [VORI] 200 mg: VORI) on single dose administration of firsocostat
20mg (N 14). Co -administration of firsocostat with PBC resulted in a moderate increase in 
firsocostat exposure (61%) indicating UGTs are involved in the metabolism of firsocostat . The 
moderate increase in GS -834773 exposure (74%) with PBC may  be due to in hibition of other 
enzy mes/transporters involved in the clearance of GS -834773. Co-administration of firsocostat
with VORI  increased firsocostat and GS -834773 exposures (37% and 44%, respectivel y) 
indicating CYP3A4 plays a small role in the elimination of both parent and metabolite.
Cohort 5: I mpact of single and multiple doses of firsocostat 50 mg once daily  on a sensitive 
CYP3A4 probe substrate (midazolam [MDZ] 2 mg: MDZ; N 12). Neither single dose nor 
multiple doses of firsocostat altered MDZ exposure (90% CIs of the % geometric mean ration 
(GMR) for AUC and C maxwith lack of effect bounds of 70- 143%) indicating firsocostat is not an 
inhibitor or inducer of CYP3A4.
Cohort 6: I mpact of single and multiple doses of firsocostat 50 mg once daily  on a represent ative 
combined oral contraceptive (drospi[INVESTIGATOR_187306] [DRSP]/EE 3/0.02 mg: DRSP/EE; N 16). There was 
no effect of single dose firsocostat on DRSP or EE exposure (90% CIs of the %GMR for AUC 
and C maxwith lack of effect bounds of 70 -143%). Multiple doses of firsocostat slightly  increased 
EE exposure (AUC infincreased ~34%) with no effect on DRSP exposure indicating firsocostat
does not induce enzy mes/transporters involved in the clearance of DRSP or EE. No loss of 
contraceptive efficacy  is expected upon administra tion of firsocostat with oral contraceptives like 
DRSP/EE. The slight increase in EE exposure is not considered clinically  significant and does 
not warrant dose modification.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 39 22 October 2019Table 1-2. Preliminary Pharmacokinetic Results from Study GS -US- 426-4074 
Evaluating DDIs with Firsocostat (20 mg or 50 mg)
Inhibitor/Inducer 
DrugFirsocostat
%GMR (90% CIs)GS-834773
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
CsA2120 
(1810, 2480)2000 
(1590, 2520)6450 
(5260, 7900)7870
(6130, [ZIP_CODE])
RIF1840 
(1570, 2150)2710 
(2160, 3400)5540
(4520, 6790)[ZIP_CODE]
(7890, [ZIP_CODE])
PBC161 
(144, 180)160 
(132, 195)174 
(148, 204)176
(145, 214)
VORI137 
(123, 152)145 
(119, 176)144 
(123, 170)140
(116, 171)
MDZ  + SD Firsocostat
%GMR (90% CIs)MDZ  + MD Firsocostat
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
Firsocostat (50 mg)111 
(99.8, 123)102 
(91.6, 115)102 
(91.4, 113)106
(94.9, 119)
DRSP + SD Firsocostat
%GMR (90% CIs)DRSP + MD Firsocostat
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
Firsocostat (50 mg)96.4 
(86.5, 107)103 
(91.5, 116)105 
(94.0, 117)116
(102, 131)
EE + SD Firsocostat
%GMR (90% CIs)EE + MD Firsocostat
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
Firsocostat (50 mg)102 
(87.6, 119)112 
(104, 122)134 
(114, 156)121
(111, 131)
SD  single dose
MD  multiple dose
Data reported to 3 significant figures
1.4.6. Study GS -US-426- 3988: A Phase 1 Open - Label, Parallel- Group, Single -Dose 
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in 
Subjects with Normal and Impaired Hepatic Function
Study  GS-US-426- 3988 is an ongoing Phase 1, open -label, parallel -group, single dose stud y 
evaluating the safet y, tolerability, and PK of firsocostat or fenofibrate in subjects with normal
hepatic function and mild, moderate, or severe hepatic impairment (CP class A, B, or C, 
respectivel y). Up to 80subjects are planned for E nrollment in 1 of 4 hepatic impairment cohorts: 
Cohort 1 (mild hepatic impairment), Cohort 2 (moderate hepatic impair ment), Cohort 3 
(severe hepatic impairment) , and Cohort 4 (mild hepatic impairment) . Within each cohort, each 
subject with impaired hepatic function (N
10 per cohort) will be matched for age (± 10 years), 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 40 22 October 2019sex, race, and bod y mass index (BMI): ±15% with a control subject wit h normal hepatic 
function (N 10 percohort). Data from health y subjects may be used in >[ADDRESS_747642] with hepatic function in >1 cohort. Subjects in Cohorts 1 and 
2 will receive a single or al dose of f irsocostat 20 mg in a fasted state on Day  1. Subjects in 
Cohort 3 will receive a single oral dose of firsocostat 5mg in a fasted state on Day 1.Subjects in 
Cohort 4 will receive a single oral dose of fenofibrate 48 mg in a fasted state on Day  1.
[IP_ADDRESS]. Subject Disposition and Demographics
As of 1 9April 2019 a total of 72subjects were dosed; 67subjects had completed study  
treatment. No subjects prematurel y discontinued study  treatment. No subjects withdrew consent, 
and no subjects were lost to follow-up.
[IP_ADDRESS]. Preliminary  Safet y Results
In the mild hepatic impairment cohort, [ADDRESS_747643] (10%) had a tre atment -related AE of facial 
flushing that was Grade 1. One other mild hepatic impairment subject had a Grade [ADDRESS_747644] had a Grade 1 headache that was 
deemed not -related to study  drug. There was no Grade 3 or 4 AEs in either cohort. No AEs led to 
dose modification, interruption, or premature discontinuation of study  drug. There were no 
SAEs, pregnancies, or deaths.
In the mild hepatic impairment cohort, 4 subjects had Grade 3 lab abnormalities. Elevations in 
GGT (2 subjects) and LDL cholesterol (2 subjects) were the most common, and all Grade 3 lab 
abnormalities of GGT and L DL were present at Screening. In the healthy  matched controls, 
2subjects also had Grade 3 L DL cholesterol lab abnormalities that were present at Day 1. In the 
moderate hepatic impairment cohort, 3 subjects had Grade 3 lab abnormalities 
(decreased lymphocy tes, hy pomagnesemia, and h yponatre mia). There were no Grade 4 lab 
abnormalities.
[IP_ADDRESS].1. Preliminary  PK Results
Preliminary  PK results from Cohorts 1 and 2 are presented below and in:
Cohort 1 (Mild Hepatic Impairment; CP A): firsocostat exposure (AUC infand C max) was 
higher in subjects with mild hepatic impairment (approximately  84% and 69%, respectively ) 
as compared to subjects with normal hepatic function. I n subjects with mild hepatic 
impairment, exposure (AUC infand C max) of the metabolite GS -834773 was also higher 
(approximately  3.9-fold high er for both). Plasma protein binding of both parent and 
metabolite were similar in subjects with mild hepatic impairment as compared to subjects 
with normal hepatic function. 
firsocostat is a hepatic OATP substrate and OATP 
expression/activity  may  be reduc ed in patients with cirrhosis. Thus, altered OATP 
expression/activity  may  contribute to the observed higher s ystemic exposure of firsocostat . 
At a dose of 20 mg once daily  (QD) in subjects with mild hepatic impairment, exposure 
margins relative to preclini cal NOAEL exposures for both parent and metabolite are expected 
to remain adequate.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 41 22 October 2019Cohort 2 (Moderate Hepatic I mpairment; CP B): firsocostat exposure (AUC infand C max) was 
higher in subjects with moderate hepatic impairment (approximately  8.7- and 9.1 -fold higher, 
respectivel y) as compared to subjects with normal hepatic function. Exposure (AUC infand 
Cmax) of the metabolite GS
-834773 was also higher (approximately  37.5- and 44.7 -fold 
higher, respectively). Plasma protein binding of both parent and meta bolite were similar in 
subjects with moderate hepatic impairment as compared to subjects with normal hepatic 
function. The increased exposure of firsocostat and GS -834773 in subjects with moderate 
hepatic impairment is likely  due to further decreases in OA TP expression/activity  relative to 
mild hepatic impairment as well as decreases in expression/activity  of enzymes involved in 
firsocostat metabolism (ie, UGTs and CYP3A4). At a dose of 20 mg QD, firsocostat plasma 
exposures in subjects with moderate hepati c impairment are ≥ 5-fold and ≥ 25- fold lower 
than exposures at the NOAEL  in the chronic toxicology  studies in dogs and rats, respectivel y.
Table 1-3. GS-US- 426-3988: Preliminary Firsocostat and GS -834773 PK 
Parameters Following a Single Dose of Firsocostat 20 mg in Subjects 
with Mild or Moderate Hepatic Impairment or Normal Hepatic 
Function
Cohort AnalyteMean (% CV) PK 
ParameterMatched Healthy 
Control (N=10)Moderate Hepatic 
Impairment (N=10)%GMR
(90%  CI)
1
(Mild HI)FirsocostatAUC inf(hr.ng/mL)70.4 
(55.2)166 
(98.2)184 
(101, 336)
AUC last(hr.ng/mL)69.6 
(55.7)161 
(98.5)181 
(99.3, 331)
Cmax(ng/mL)25.4 
(80.6)50.9 
(90.3)169 
(87.5, 325)
GS834773AUC inf(hr.ng/mL)8.29 
(69.6)48.1 
(123)387 
(177, 846)
AUC last(hr.ng/mL)7.38 
(79.0)46.3 
(125)430 
(187, 990)
Cmax(ng/mL)2.29 
(91.8)12.9 
(125)391 
(164, 935)
2
(Moderate 
HI)FirsocostatAUC inf(hr.ng/mL)65.9 
(52.3)687 
(72.8)867
(484, 1550)
AUC last(hr.ng/mL)64.5 
(51.5)681 
(72.9)879
(491, 1580)
Cmax(ng/mL)20.1 
(60.2)198 
(60.0)905
(539, 1520)
GS834773AUC inf(hr.ng/mL)5.9 
(57.5)399 
(135)3750
(1640, 8560)
AUC last(hr.ng/mL)5.1 
(62.9)396 
(136)4410
(1900, [ZIP_CODE])
Cmax(ng/mL)1.4
(81.2)77.3 
(72.5)4470
(2190, 9130)
Data presented to 3 significant figures
Based on the preliminary PK data from this study  as well as the overall safety  profile of 
firsocostat , dose adjustments are not considered necessary  in subjects wi th mild hepatic 
impairment.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 42 22 October [ZIP_CODE].4.6.3. A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study  Evaluating the 
Safety , Tolerabilit y, and Efficacy of Firsocostat in Subjects with Nonalcoholic 
Steatohepatitis (GS -US-426-3989)
Please refer to the 
firsocostat IB for additional details.
1.5. Rationale for This Study
NASH involves a complex interplay  between hepatocy tes, immune cells, and hepatic stellate 
cells that perpetuates a pathological cy cle of hepatocy te injury , inflammation and fibrosis 
{Caligiuri 2016 }. Increased sy nthesis and accumulation of fatt y acids in hepatocy tes leads to 
lipotoxicity , a state characterized by  [CONTACT_569937], bile acids, 
ROS, growth factors, and ultimately  hepatocy te cell death {Neuschwander -Tetri 2010 }. These 
metabolic stress signals directly
 promote the activation and differentiation of hepatic stellate 
cells into my ofibroblasts, the primary  source of collagen and extracellular matrix that causes 
fibrosis. I n addition, hepatocy te lipotoxicity  promotes an immune response by  [CONTACT_569938], which produce ROS, growth factors and cytokines such as transforming growth 
factor beta (TGF -and platelet -derived growth factor ( PDGF ), that further increase 
myofibroblast activation, migration, proliferation and survival, and result in fibrosis {Lee 2015 }. 
Based on the multiple biological pathway s involved in the pathogenesis of NASH, and the 
heterogeneity
 of the patient population, it is likely  that a combination of drugs that have distinct 
mechanisms of action will be required to achieve optimal therapeutic benefit.
Both human and animal studies have shown a beneficial effect of GL P-1 RA on liver lipid 
metabolism ,inflammation, and progression of fatty liver to NASH {Gao 2015, Lee 2012 , Mells 
2012, Panjwani 2013 }.The investigator sponsored study  Liraglutide Efficacy  and Action in 
NASH (LEAN), enrolled 52 overweight subjects with and without T2D, with biopsy - confirmed 
NASH to receive liraglutide s.c. or placebo once daily . After 48 weeks of treatment, 9 out of 
23
(39%) subjects treated with liraglutide had resolution of NASH with no worsening of fibrosis 
(relative risk 4.3 [1.0 17.7] 95% CI ; p 0.019) compared to 2 out of 22 (9%) subjects treated 
with placebo. Furthermore, significantly  fewer patients treated with liraglutide had worsening of 
fibrosis compared to placebo {Armstrong 2016 }.As semaglutide is structurally  similar to 
liraglutide with similar mechanism of action and with potential for more pronounced effect on 
glycemic control and body weight, semaglutide is thought to be a potential candidate for 
treatment of NASH, both alone and in combination with other agents. 
As previously  noted, increased rates of hepatic DNL  and insufficient fatty  acid oxidation lead to 
hepatic steatosis and associated lipotoxicity, which are implicated in the etiology  and progression 
of NASH. By  [CONTACT_569939], firsocostat has been shown to reduce steatosis and fibrosis in 
animal models of NASH and to reduce DNL b y >70% at doses of 20 mg daily  in humans. In a 
recentl y-completed Phase 2 study  in subjects with NASH (GS -US-426- 3989), firsocostat led to 
improvement in hepatic st
eatosis, liver biochemistry , and markers of fibrosis. 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 43 22 October 2019FXR agonism has been shown to reduce hepatic lipid and bile acid s ynthesis due to down 
regulation of sterol regulatory  element binding protein -1c (SREBP -1c) and cytochrome 
P450 7A1 (CYP7A1), respective ly, as well as reduce insulin resistance and hepatic 
gluconeogenesis {Zhang 2006}. Animal models have demonstrated the ability  of cilofe xorto 
reduce hepatic fibrosis in a choline -deficient high fat diet/NaNO 2rat model of NASH and to 
reduce hepatic steatosis in obese mice fed a fat and carboh ydrate rich diet. In the proof of 
concept stud y (GS -US-384-3914), cilofexor led to statistically  significant reductions in hepatic 
steatosis and GGT, and thus, cilofexor is postulated to have these and other benefits with longer 
duration of dosing. 
Preclinical studies in animal models of NASH have demonstrated that combinations of an FXR 
agonist and A CC inhibitor lead to greater efficacy to reduce hepatic steatosis and measures of 
liver fibrosis compared to the respective monotherapi[INVESTIGATOR_014]. Combination toxicology  studies have 
revealed no new toxicities of the combination of cilofexor and firsocostat . 
In the proof of concept combination study  (GS-US-384- 3914), 20 subjects re ceived firsocostat
20mg and cilofexor 30 mg once dail y for 12 weeks. 73.7% of subjects (14 of 19 evaluable 
subjects) had at least a 30% relative reduction in MRI -PDFF .The subjects on this regimen also 
had significant median relative reductions in liver biochemistry  (i.e.,ALT, GGT) and 
FibroSure®/FibroTest®after 12 weeks of treatment. From a safet y perspective, these subjects had 
similar rates of AEs compared to monotherap y treatment with firsocostat orcilofexor treatment 
alone for 12 weeks in this study .  
In previous and ongoing studies with firsocostat and cilofexor (GS-US-426-3989, 
GS-US-402- 1852, GS -US- 384-3914, and GS -US-454- 4378), subjects have been concurrentl y 
treated with GLP -[ADDRESS_747645] efficacious, as well as the hypothesis that weight loss is a key  driver of
NASH resolution in patients without advanced fibrosis , supported by  [CONTACT_569940] , this study  aims to evaluate the safet y and tolerability of combining semaglutide 
(anagent approved for treatment of t ype 2 diabetes, and in clinical testing for weight loss 
treatment and NASH ) with cilofexor and firsocostat which address separate but complementary  
pathophy siologic pathway s in this complex disease.  
1.5.1. Rationale for Dose Selection of S emaglutide
The proposed target dose of semaglutide 2.4 mg once weekl y in the Phase 3 weight management 
study  (NN9536) is based on an integrated evaluation of efficacy  and safety  as well as on 
exposure (C avgand C max). Results from the Phase2 dose -finding 
study  (NN9536- 4153) in
subjects with obesity  showed that the semaglutide 0.[ADDRESS_747646] onweight loss while display ing an a cceptable tolerability  profile . Furthermore, data from 
the semaglutide s.c. T2D development program (SUSTAIN trials with once
-weekl y dosing and 
study  NN9535 -4191 with once -daily s.c. dosing of up to 0.3 mg/day) did not support the 
hypothesis that once -daily  dosing provides better gastrointestinal (GI) tolerability  as compared to 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 44 22 October 2019once -weekl y dosing. Hence, the proportion of subjects with GI AEs and the ra tes of such events 
were generally  higher in study  NN9535 -4191 and in study NN9536 -4153 where semaglutide was 
dosed once dail y as compared to the Phase 3a trials where semaglutide was dosed once weekly.
Based on population pharmacokinetic modelling, it was estimated that the C maxat steady -state, 
with a once -weekl y maintenance dose of 2.4 mg semaglutide s.c., will not exceed that obtained 
with the once -daily 0.4 mg semaglutide s.c. dose investigated in study  NN9536 -4153. When 
comparing the simulated human ex posure at 2.4 mg/week to the animal exposures at the 
NOAEL, exposure ratios are above 1, indicating that exposure at 2.4 mg is supported by  [CONTACT_569941]
. Consequently , the proposed semaglutide s.c. target dose for the P hase 3 
weight management d evelopment program is 2.4 mg once weekly .
It is well known that to mitigate GI side effects with GL P-1 RA treatment, dose escalation to the
target dose is required. Based on experience from the semaglutide s.c. T2D development
program and study  NN9536 - 4153 , a similar fixed dose -escalation regimen was selected, with 
dose escalation every  4 weeks until the target dose of 2.4 mg is reached after 16 weeks.
1.5.2. Rationale for the Dose Selection of Cilofexor
This study  will evaluate the safet y and tolerability  of 30mg and 100mg cilofexor QD in 
combination with semaglutide over 2 4 weeks in subjects with NASH. These doses were selected 
based on short -term safety , PK and PD results from Study  GS-US-402- 1851 in healthy  subjects.  
In the Phase 1 stud y GS -US-
402-1851, cilofexor was tested at doses ranging from 10 to 300 mg 
once dail y for up to 14 days and was well tolerated. Across the range of cilofexor doses 
evaluated, doses 
≥ [ADDRESS_747647] 30% in hepatic fat 
measured b y magnetic resonance imaging -proton density  fat fraction (MRI -PDFF) was observed 
in 38.9% of patients treated with cilofexor 100 mg (p 0.011 vs placebo), 14% treated with 
cilofexor 30 mg (p 0.87), and 12.5% with placebo. I mprovements in liver biochemistry  tests 
(serum GGT) and markers of reduced bile acid s ynthesis (serum C4 and bile acids) were 
observed in the 30 mg and 100 mg arms of cilofexor -treated patients. Cilofexor was generally  
well tolerated; moderate to severe p ruritus, or itching, occurred in 14% of patients in the 
cilofexor 100 mg arm compared to 4% in the cilofexor [ADDRESS_747648] infection, headache and fatigue. Treatment was discontinued due to adverse 
events in one patient treated with cilofexor 100 mg (2%), five patients treated with cilofexor 
30mg (9%), and two patients with placebo (7%).
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 45 22 October [ZIP_CODE].5.3. Rationale for the Dose Selection of Firsocostat
The dose of firsocostat chosen for evaluation in this study , 20 mg QD, is supported by [CONTACT_395494] , 
tolerability  and effects of firsocostat on DNL from studies 0976-101, 0976- 102, and 0976 -103 
described in the IB, the efficacy  observed in the Phase 2 NASH stud y (GS -US-426- 3989), and 
the safet y of firsocostat in subjects wi th cirrhosis due to NASH (proof of concept study  
GS-US-
384-3914), including those wi thmild hepatic impairment (GS- US-426-3988). In healthy  
subjects, single doses of firsocostat up to 1000 mg or multiple daily  doses (10 days) of 
firsocostat up to 200 mg were administered. In healthy  but overweight or obese subjects, a single 
firsocostat dose of 20 mg resulted in a mean inhibition of fractional DNL of 71% . In study  
GS-US-
426-3989, firsocostat 5 mg and 20 mg were evaluated for 12 weeks in subjects with mild 
to moderate fibrosis due to NASH. Both dose levels demonstrated similar safety  profil es, but 
only the 20 mg dose showed statistically  and clinically  significant reductions in MRI -PDFF. 
firsocostat 20 mg also had larger reductions in liver biochemistry  (i.e.
, ALT) and serum markers 
of fibrosis (i .e., tissue inhibitor of metalloproteinase 1 (TIMP-1)and procollagen III amino 
terminal peptide (PI[INVESTIGATOR_120861] )). In stud y GS -US-
426-3989, approximately  40% of subjects were 
presumed to have advanced fibrosis at baseline based on MRE values ≥
3.64 kPa and/or ELF™
Test scores ≥ 9.8. These subjects showed si milar efficacy  and safet y profiles as subjects with less 
advanced fibrosis according to these noninvasive markers of fibrosis. Also, subjects with 
cirrhosis due to NASH have been dosed with firsocostat [ADDRESS_747649] been 
conducted in rats and dogs, respectivel y, at exposure margins multiple folds above the expecte d 
clinical exposure. Firsocostat exposures in non- cirrhotic subjects are expected to remain 
> 48- and 206 -fold lower than the firsocostat exposures observed at the NOAEL s in the 39 -week 
dog and 26 -week rat toxicity  studies, respectivel y. Based on preliminar y data from Study 
GS-US-426-3988, firsocostat exposures in subjects w ith mild hepatic impairment (CP A) are 
expected to remain ≥ 22 and ≥[ADDRESS_747650] levels of 
morbidity  and mortality  are found in NASH patients with advanced fibros is and cirrhosis 
{Ekstedt 2014, Yeh 2014 }. Thus, evaluating agents in thispatient population is anticipated to
have the greatest impact on morbidity  and mortality . 
Protocol GS -US-454-[ADDRESS_747651] a clinical diagnosis of NAFL D with 
evidence of ≥ 10% hepatic steatosis on MRI -PDFF {Bannas 2015 }, a Screening FibroTest®
<0.75 (unless historical liver biopsy  does not reveal cirrhosis), and a FibroSca n®with liver 
stiffness >[ADDRESS_747652] a high 
probability  of NASH with fibrosis, a population with a large unmet medical need {Loomba 
2014}.
Ongoing clinical trials are evaluating the efficacy  of cilofexor and firsocostat in combination for 
subjects with NASH with bridging fibro
sis and compensated cirrhosis. Given the potential 
benefits of s emaglutide in the NASH patient population, this study  will evaluate the safety  and 
tolerability  of a GL P -[ADDRESS_747653] as a component of future combination therap y for NASH 
(i.e., in addition to cilofexor or firsocosta t alone, or to both). 
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Protocol GS-US-454-[ADDRESS_747654] ive of this study is as follows: 
• To evaluate the safety and tolerability of study drug(s) in subjects with NASH . 
I 
I 
I 
I 
I 
I 
CONFIDENT IAL Page 47 Final 
Amendment2 
22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 48 22 October [ZIP_CODE]. STUDY  DESIGN
3.1. Study Design
This is a proof of concept, open-label stud y evaluating the safet y, tolerability , and efficacy  of 
monotherap y and combination regimens in subjects with NASH.
Subjects meeting the study ’s entry  criteria will be randomly  assigned in a 1:1:1:1:1 ratio to 1 of 5 
treatment groups, with approximately  20 subjects in each group, as shown in the figure below:
Figure 3
-1. Overall Study Design
Randomization will be stratified b y the presence or absence of type 2 diabetes mellitus, as 
determined b y medical history or based on the Screening laboratory  values if previously  
undiagnosed (hemoglobin A1c [HbA1c] ≥ 6.5%).
3.2. Study Treatments
Subjects meeti ng the study ’s entry  criteria will be randomly  assigned in a 1:1:1:1:[ADDRESS_747655] Selection
This study  will enroll approximately  100 subjects with a clinical diagnosis of nonalcoho lic fatty  
liver disease (NAFLD) with a S creening FibroTest®< 0.75 (unless all historical li ver biopsies do 
not reveal cirrhosis) , a Screening MRI -PDFF with ≥ 10% steatosis (as assessed by  [CONTACT_129211]) , and a S creening FibroScan®with liver stiffness ≥ 7 kPa, OR subjects with a historical
liver biopsy  within 6 months of the date of the Screening Visit consistent with NASH 
(defined asthe presence of steatosis, inflammation, and ballooning) with stage 2 -3 fibrosis 
according to the NASH Clinical Research Network (CRN) classification (or equi valent).
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1) Males and females between 18-75 years of age inclusive ,based on the date of the Screening 
Visit;
2)Willing and able to provide informed consent prior to any  study  specific procedures being 
performed;
3)Subjects must meet all of the following conditions (a-d) OR (e):
a.Clinical diagnosis of nonalcoho lic fatt y liver disease (NAFLD);
b.Screening FibroTest®< 0.75, unless all previo us historical liver biopsies do not reveal 
cirrhosis. In subjects with Gilbert’s sy ndrome or hemoly sis, FibroTest®will be calculated 
using direct bilir ubin instead of total bilirubin;
c.Screening MRI -PDFF with ≥ 10% steatosis, as assessed b y the central rea der. Historical 
MRI -PDFF within 4 weeks of the date of the Screening Visit may  be used if deemed 
acceptable b y the central reader ;
d.Screening FibroScan®with liver stiffness ≥ 7 kPa. Historical FibroScan® within 4 weeks 
of the date of the Screening Visit is acceptable;
OR
e.A
n historical liver biopsy within 6 months of the date of the Screening Visit consistent 
with NASH (defined as the presence of steatosis, inflammation, and ballooning) with 
stage 2 -3 fibrosis according to the NASH Clinical Research Network (CRN) 
classification (or equivalent). Report will be reviewed by  [CONTACT_1689] ;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 53 22 October [ZIP_CODE])Subject has the following laboratory  parameters at the Screening V isit, as determined by  [CONTACT_19979] :
a.Alanine aminotransferase (ALT) ≤ [ADDRESS_747656] ;
b.eGFR ≥ 30 milli
liter/minute (mL /min), as calculated by  [CONTACT_36583] s tudy equation ;
c.HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c is unable to be resulted);
d.INR ≤ 1.2, unless due to therapeutic anti -coagulation therap y;
e.Platelet count ≥ 100,000/ μL;
f.Total bilirubin < 1.[ADDRESS_747657] unless alternate etiology such as Gilbert’s s yndrome present ;
g.Calcitonin ≤ 100 ng/L ;
5)Body Mass Index (BMI) > 23kg/m2and bod y weight of > 60 kg ;
6) A negative serum pregnancy  test is required for female subjects of childbearing potential as 
defined in Appendix 3;
7)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3.
4.3.
Exclusion Criteria
Subjects who meet anyof the following exclusion criteria are not to be enrolled in this study .
1)Documented weight loss > 5% within 6 months of the date of the Screening Visit ; 
2)Any historical liver biopsy  consistent with cirrhosis ;
3) Pregnant or lactating females;
4)Alcohol consumption greater than 21 oz/week for males or 14oz/week for females 
(1oz/30 mL of alcohol is present in 1 12oz/360 mL beer, 1 4oz/120 mL  glass of wine, and a 
1oz/30 mL measure of 40% proof alcohol);
5) Positive urine screen for amphetamines, cocaine or opia tes (ie, heroin, morphine) at 
Screening. Subjects on stable methadone or buprenorphine maintenance treatment for at least 
6months prior to the date of Screening Visit may be included in the study . Subjects with a 
positive urine drug screen due to prescription opi[INVESTIGATOR_2480] -based or amphetamine -based 
medication are eligible if the prescription and diagnosis are reviewed and approved b y the 
investigator;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 54 22 October [ZIP_CODE])Any history  of decompensated liver disease, including ascites, hepatic encephalopathy , or 
variceal bleed ing;
7)Other causes of liver disease, including but not limited to: alcoholic liver disease, hepatitis B, 
hepatitis C, autoimmune disorders (eg, primary  biliary  cholangitis [PBC], primary  sclerosing 
cholangitis [PSC], autoimmune hepatitis), drug -induced hepa totoxicity , Wilson disease, 
clinically  significant iron overload, or alpha -1-antitry spin deficiency  requiring treatment;
8)History  of liver transplantation;
9)History  of hepatocellular carcinoma;
10)Weight reduction surgery in the past 2 y ears or planned during t he study ;
11)Chronic hepatitis B (HBsAg positive);
12)Chronic hepatitis C (HCV RNA positive). Subjects cured of HCV infection less than 2 years 
prior to the date of the 
Screening V isit are not eligible;
13)HIV Ab positive;
14) Unstable cardiovascular disease as define d by [CONTACT_39132]:
a.Unstable angina, myocardial infarction, coronary artery b ypass graft surgery  or coronary  
angioplast y within 6 months prior to the date of the Screening Visit;
b. Transient ischemic attack or cerebrovascular accident within 6 months prior to the date of 
the Screening Visit;
c.Symptomatic obstructive valvular heart disease or hy pertrophic cardiom yopathy ;
d.Symptomatic congestive heart failure;
e.Uncontrolled or recurrent ventricular tach ycardia or other arrh ythmia requiring an 
automatic impl antable cardioverter defibrillator (AI CD). Stable, controlled atrial 
fibrillation is allowed;
f.An emergency  room visit or hospi[INVESTIGATOR_569901] 
6 months prior to the date of the Screening Visit;
15)History  of a malignancy  within 5 y ears of the date of the Screening Visit with the following 
exceptions:
a.Adequatel y treated carcinoma in situ of the cervix ;
b.Adequatel y treated basal or squamous cell cancer or other localized non -melanoma skin 
cancer ;
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 55 22 October 201916)Presence of acute pancreatitis within the past 180 day s prior to the date of the Screening 
Visit;
17)History  or presence of chronic pancreatitis;
18)Presence or history  of type 1 diabetes mellitus ;
19)For subjects with t ype 2 diabetes diagnosed prior to the date of the Screening Vis it OR on 
Screening Visit labs (defined as HbA1c ≥6.5%), subjects must have no evidence of 
uncontrolled and potentially  unstable retinopathy  or maculopathy  as determined by : 
a.A fundus exam performed in the [ADDRESS_747658]’s visual function since this historical fundus exam in 
the opi[INVESTIGATOR_871], then the fundus exam must be repeate d;
OR
b.
A fundus exam performed between the date of the Screening Visit and Enrollment 
(Day  -14) 
Pharmacological pupil
-dilation is a requirement in both of the above cases unless using a 
digital fundus photography  camera specified for non -dilated examination;
20)Personal or first degree relative(s) history  of multiple endocrine neoplasia ty pe 2 or 
medullary  thyroid carcinoma;
21)Treatment with GLP -1 RAs in the period from 90 days prior to the date of the Screening 
Visit;
22)Subjects on Vitamin E regimen ≥800 IU/day  must be on a stable dose (defined as no changes 
in prescribed dose, new Vitamin E containin g medications, or discontinuation) for at least 
180 day s prior to the date of the Screening Visit and in the period between the date of the 
Screening Visit and Enrollment (Day  -14);
23)Subjects on antidiabetic medications must be on a stable dose for at least 90 day s prior to the 
date of the Screening Visit and in the period between the date of the Screening Visit and 
Enrollment (Day  -14); 
24)Use of an y prohibited concomitant medications as described in Section 5.6;
25)Any investigational medication or device within 30 day s or within 5 half -lives of the prior 
investigational agent (whichever is longer) prior to the date of the Screening Visit throughout 
the study  (e.g., obeticholic acid, elafibranor, and cenicriviroc) is prohibited;
26)Known hy persensitivity  to the study  drug, the metabolites, or formulation excipi[INVESTIGATOR_841].
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 56 22 October [ZIP_CODE]. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization
An Interactive Web Response System ( IWRS ) will be used for centralized randomization and 
treatment assignment. Randomization will be stratified by  [CONTACT_569942] 2 
diabetes mellitus, as determined by  [CONTACT_569943] (HbA1c ≥ 6.5%).
Investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the IWRS. Study  drugs will be dispensed by  [CONTACT_569944], or designee 
to the subjects.
Study  drugs will be dispensed in an op en-label fashion to the subjects.
5.2. Description and Handling of S emaglutide 3.0 mg/m L
The drug product formulation for the semaglutide solution for injection has the composition 
shown in Table 5-1. All other ingredients than the active drug substance are commonly  used 
excipi[INVESTIGATOR_840]. Semaglutide solution for injection is a colorless or almost colorless liquid, free from 
turbidity  and essenti ally free from particul ate matter.
Table 5-1. Composition of Semaglutide S olution for I njection
Nam e ofingredient Function Pharm acopoeia
Drug substanc e
Semaglutide Active ingredient Novo Nordisk A/S
Other ingredients
Disodium hydrogen phosphate, 
dihydrate Buffering agent USP/Ph. Eur
Propylene glycol Isotonic agent USP/JP/Ph. Eur
Phenol Preservative USP/JP/Ph. Eur
HCl pH adjustment USP/JP/Ph. Eur
NaOH pH adjustment USP/JP/Ph. Eur
Water for injection Solvent USP/JP/Ph. Eur
Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice Annex 13 (Investigational Medicinal 
Products), and/or other local regulations.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 57 22 October [ZIP_CODE].2.1. PDS290 pen -injector for S emaglutide for use in C linical Trials
Device Information
The PDS290 pen -injector for semaglutide is a dial -a-dose prefi lled device integrated with a 3 mL 
cartridge filled with semaglutide 3.0 mg/mL. The pen -injector can deliver doses from [ADDRESS_747659]®and NovoFine®disposable needles. A new needle must be attached before and 
discarded after each injection.
Specific instructions for correct handling of the PDS290 pen- injector for semaglutide are 
included in the directions for use (DFU) provided to trial sites and to be provided directl y to 
subjects. Storage instructions are printed on the drug product label and are also provided in the 
Site Operations Manual. Investigators must ensure that these instructions are strictly  followed.
Regulatory Status
The PDS290 pen -injector for semaglutide complies with relevant standards and regulations. 
Several other variants of PDS290 pen-injectors have been approved worldwide since 2010 for 
s.c. injection of insulins (under the brand name [CONTACT_569965]®),growth hormone
(under the brand name [CONTACT_569966]®)and GLP -1 products (Saxenda®,Ozempic®).
Existing Clinical Da ta
The adequate safet y and performance of the PDS290 pen -injector for semaglutide (3.0 mg/mL) 
for the intended purpose are demonstrated through the literature review as well as the anal ysis of 
human factors engineering data and post -market safety  data for the PDS290 pen- injector family . 
It is concluded that the PDS290 pen -
injector for semaglutide (3.0 mg/mL) gives a favorable 
benefit -risk profile for administration of semaglutide in NASH clinical trials.
Thus far, no clinical trials have been completed with the PDS290 pen- injector for semaglutide 
(3.0 mg/mL) in NASH clinical programs.
Protocol GS -US-454-[ADDRESS_747660] be stored at 2 8°C. Exposure to light and freezing must be avoided. Under 
these storage conditions, semaglutide products will retain ful l biological activity  until the expi[INVESTIGATOR_569902]. As for other parenteral preparations, the semaglutide trial products 
should be inspected visually  for particulate matter and discoloration prior to administration. The 
products should be disc arded if either is present. Only  use the semaglutide solution for injection 
if it has colorless or almost colorless appearance free from turbidit y and essentially free from 
particulate matter.
5.2.3. Shelf -life and in -use time for Semaglutide in PDS290 
The shelf life of semaglutide in the PDS290 pen- injector is up to 36 months wh
en stored at 
2-8°C. The product should not be used after the expi[INVESTIGATOR_569903] , Inc
.The in- use time is up to 
8weeks between 8-30°C. Do not refrigerate. Exposure to excessive heat and light as well as 
freezing must be avoided during use. 
5.3. Description and Handling of Cilofexor (GS-9674) 
5.3.1. Formulation
Cilofexor is supplied as 100 mg and 30 mg strength (as free form equivalent) tablets. The tablets 
contain cilofexor -02 (tromethamine salt) and the following inactive ingredients: mannitol, 
microcry stalline cellulose, crospovidone, magnesium stearate and film
-coatin g material 
polyvinyl alcohol, pol yethylene gly col, titanium dioxide, talc, y ellow iron oxide and black iron 
oxide. Cilofexor 100 mg tablets are capsule -shaped, film -coated green tablets debossed with 
“100” on one side and “GSI” on the other side. Cilofexor 30mg tablets are round, film -coated 
green tablets debossed with “30” on one side and “GSI” on the other side.
5.3.2. Packaging and Labeling
Cilofexor tablets are packaged in white, high -density  poly ethylene (HDPE) bottles. Each bottle 
contains 30 tablets, silic a gel desiccant, and poly ester packing material. Each bottle is enclosed 
with a white, continuous thread, child -resistant poly propy lene screw cap with an 
induction- sealed, aluminum -faced liner.
Study  drug(s) to be distributed to centers in the US shall be labeled to meet applicable 
requirements of the [LOCATION_002] Food and Drug Administration (FDA) and/or other local 
regulations.
5.3.3. Storage and Handling
Study  drug cilofexor should be stored below 30°C (86 °F). Storage conditions are specified on 
the label.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 59 22 October 2019Until dispensed to the subjects, all bottles of study  drugs should be stored in a securely  locked 
area, accessible only to authorized site personnel. 
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact [CONTACT_10850] . 
Appropriate precautions should be followed to avoid direct ey e contact [CONTACT_569945].
5.4. Description and Handling of Firsocostat (GS-0976) 
5.4.1. Formulation
Firsocostat tablets are round, plain -faced, film -coated white tablets containing 20 mg firsocostat . 
In addition to the active ingredient, firsocostat tablets contain the following inactive ingredients: 
lactose monohy drate, microcry stalline cellulose, croscarmellose sodium, magnesium stearate, 
polyvinyl alcohol, titanium dioxide, poly ethylene gl ycol, and talc.
5.4.2. Packaging and Labeling
Firsocostat tablets a re packaged in white HDPE bottles. Each bottle contains 30 tablets and 
polyester packing material. Each bottle is enclosed with a white, continuous thread, 
child- resistant poly propylene screw cap with an induction -sealed and aluminum- faced liner.
Study  drug(s) to be distributed to centers in the US shall be labeled to meet applicable 
requirements of the [LOCATION_002] Food and Drug Administration (FDA) and/or other local 
regulations.
5.4.3. Storage and Handling
Firsocostat tablets should be stored at controlled room temperature of 25 °C (77 °F); excursions 
are permitted between 15 °C and 30 °C (59 °F and 86 °F). Storage conditions are specified on 
the label. 
Until dispensed to the subjects, all bottles of study  drugs should be stored in a securely  locked 
area, acc essible onl y to authorized site personnel. 
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact [CONTACT_10850] . 
Appropriate precautions should be followed to avoid direct ey e contact [CONTACT_279383].
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 60 22 October [ZIP_CODE].5. Dosage and Administration 
The administration of study  drug will be recorded in the source documentation and in the 
electronic case report form ( eCRF ).
Firsocostat and cilofexor tablets will be provided by  [CONTACT_10869], Inc. and semaglutide 
3.0mg/ml in PDS290 pen-injectors will be provided by[CONTACT_10869], Inc. and manufactured 
by [CONTACT_3454] , Inc. Subjects will take semaglutide s ubcutaneousl y with a PDS290 
pen-injector at approximately  the same time each week. 
Subjects should be instructed to inject 
semaglutide once -weekl y at the same day  of the week throughout the trial. Injections may  be 
administered in the thigh, abdomen or upper arm, at an y time of day irrespective of meals. 
Subjects should be encouraged to inject in the same area throughout the trial, but changing 
betwee n left and right side is allowed. Subjects will take firsocostat and/orcilofexor tablets
(ifapplicable) at approximately  the same time each day , with or without 
food, swallowed whole 
with water. For firsocostat and cilofexor ,a dose will be considered missed if the subject cannot 
take the complete dose within [ADDRESS_747661] the scheduled dosing day  of the week. 
If ≥ [ADDRESS_747662] should be encouraged to 
recommence the treatment if considered safe as per the investigator’s discretion and if the subject 
does not meet an y of the discontinuation criteria. The trial product should be continued as earl y 
as the situation allows. The missed doses should not affect the scheduled dosing day  of the week. 
The start dose for re -initiation of trial product i s at the investigator’s discretion. I n case of 
questions related to re -initiation of trial product, the investigator should consult the Medical 
Monitor .
Study  drug dosing and administration will occur as fo llows, based on-treatment group 
randomization:
Treatment Group A: Semaglutide administered subcutaneousl y with pre -filled pen -injector 
once weekl y
Treatment Group B: Semaglutide administered subcutaneousl y with pre -filled pen -injector 
once weekl y, one firsocostat [ADDRESS_747663] to 
food
Treatment Group C: Semaglutide administered subcutaneousl y with pre -filled pen -injector 
once weekl y, one cilofexor [ADDRESS_747664] to 
food
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 61 22 October 2019Treatment Group D: Semaglutide administered subcutaneousl y with pre -filled pen -injector 
once weekl y, one cilofexor [ADDRESS_747665] to 
food
Treatment Group E: Semaglutide administered sub
cutaneousl y with pre -filled pen -injector 
once weekl y, one firsocostat [ADDRESS_747666] to food
5.5.1. Management of Semaglutide Dose Escalation
After randomization semaglutide will be initiated with a starting value of 8 ( 0.24 mg), as shown 
on the dose counter of the pre -filled pen -injector, for the first [ADDRESS_747667] Dose VolumeValue shown in the 
dose counter Duration
Semaglutide 
3.0mg/mL PDS2900.24 mg 80 μl 8 Day 1* through Week 4
Semaglutide 
3.0mg/mL PDS2900.50 mg 170 μl 17 Weeks 5 through 8
Semaglutide 
3.0mg/mL PDS2901.0 mg 340 μl 34 Weeks 9 through 12
Semaglutide 
3.0mg/mL PDS2901.7 mg 570 μl 57 Weeks 13 through 16
Semaglutide 
3.0mg/mL PDS2902.4 mg 800 μl 80 Weeks 17 through 24
* Subject will take first dose of study drugs on site at Day 1.
If a subject does not tolerate the planned [ADDRESS_747668], as per the 
investigator’s discretion. It is recommended that the subject makes at least one attempt to 
escalate to the recommended target dose of s.c. 2.4 mg once -weekl y, as per the investigator’s 
discretion.
It is recommended that the investigator contact [CONTACT_569946].
Protocol GS -US-454-[ADDRESS_747669] s on Vitamin E regimen ≥ 800 IU/day  must be on a stable dose (defined as no changes in 
prescribed dose, new Vitamin E containing medications, or discontinuation) for at least 180 days 
prior to the date of the Screening Visit and in the period between the date of the Screening Visit
and Enrollment (Day  -14). If possible, the doses of these medications should remain stable 
through the end of stud y.
Subjects treated with insulin at the date of the Screening Visit :
Throughout the trial, insulin dose should be titrated at the discretion of the investigator. 
For the individual subject, increasing the insulin dose before two weeks after the end of 
the final dose escalation should be avoided, unless required to control a cute 
hypergly cemia and acute diabetic complications.
Subjects treated with insulin and HbA1c ≤ 8.0 % at the date of the S creening Visit : 
Subjects treated with semaglutide in combination with insulin may  have an increased risk 
of hypoglycemia . The risk of hy poglycemia can be lowered b y reducing the dose of 
insulin, and a dose reduction at randomization and throughout the trial should be 
considered at the discretion of the investigator.
Subjects treated with sulfony lureas at the da teoftheScreening Visit :
Subjects treated with semaglutide in combination with a sulfony lurea may  have an 
increased risk of hy poglycemia . The risk of hy pogly cemia can be lowered by  [CONTACT_569947], and a dose reduction at randomization and throughout the trial 
should be considered.
Treatment with GLP -1 RAs, other than semaglutide, is prohibited in the period from 90 days 
prior to the date of the Screening Visit and through the end of study . 
Any investigational medication or device within 30 day s or within 5 half -lives of the prior 
investigational agent (whichever is longer) prior to Screening up to and through the end of study  
(eg, obeticholic acid, elafibranor, and cenicriviroc) is prohibited. 
The following medications are prohibited for all treatment groups, fr om 30 day s prior to Day  1
and through the end of study :
Any medication or supplement prescribed for weight loss.  
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 63 22 October 2019Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducers 
of drug transporters OATP1B1 or 1B3, potent or moderate inducers of CYP2C8, or potent 
inducers of CYP3A4) with study  drug(s) may  result in PK interactions resulting in increases 
or decreases in exposure of study  drug(s) 
Examples of medications that are prohibited or which should be used with caution are listed 
below in Table 5-3.
Table 5-3. List of Representative Disallowed and Use with Caution Medicationsa
Disallowed [ADDRESS_747670]. John’s Wort, Echinacea, milk thistle (ie, silymarin), Chinese herb sho-saiko -to (or Xiao -Shai-Hu-Tang)
Otherd: gemfibrozil, modafinil
Agents to be used with Caution from  30 days prior to Day 1 through End of Treatm ent
antacidse
cholestyramine, colestipol, colesevelemf
a Not all of these example medications may be approved where the study is being conducted; please refer to local product 
information.
b Intra articular, topi[INVESTIGATOR_2855], nasal, or inhaled routes are allowed. Chronic systemic use of corticosteroids equivalent to 
prednisone > 10 mg/day for > 2 weeks is not allowed. Use for ≤ 2 weeks total is allowed.
c H2Receptor antagonists can be taken up to 3 days prior to Day 1.
d May result in an increase or decrease in the concentration of study dru gs.
e Antacids that directly neutralize stomach pH (ie, Tums, Maalox) are permitted but may not be taken within 4 hours 
(before or after) oral study drug administration.
f Bile acid sequestrants are permitted but may not be taken within 4 hours (before or after) oral study drug administration.
Protocol GS -US-454-[ADDRESS_747671] 
(IMP) and Devices
The investigator is responsible for ensu ring adequate accountability  of all used and unused
deuterated water, study  drug ,kits,and devices . This includes acknowledgement of receipt of 
each shipment of deuterated water, study  drug and/ordevices (quantity  and condition). All used 
and unused deuterated water, study  drug and/ordevices dispensed to subjects must be returned to 
the site.
IMP and device accountability  records will be provided to each study  site to:
Record the date received and quantity  of deuterated water, study  drug and/ordevices
Record the date, subject number , deuterated water, study  drug lot/
kit number and/ordevices 
dispensed
Record the date, quantity of used and unused deuterated water, study  drug and/or devices
returned, along with the initials of the person recording th e information.
5.7.1. I nvestigational M edicinal Product and Device Return or Disposal
Study  drug return disposal will be performed as outlined in Section 9.1.8.
Protocol GS -US-454-[ADDRESS_747672] screened and/or enrolled in the study  are 
presented in tabular form in Appendix 2and described in the text that follows. Additional 
information is provided in the study  procedures manual .
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study  prior to E nrollment and throughout the study. 
Documentation of the personally  signed and dated informed consent of each subject, using the 
study -specific ICF, is required before initiating the Screening process.
After written informed consent has been obtained and eligibility  to participate establishe d, 
investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the interactive web response system ( IWRS).
Entry  into Screening does not guarantee Enrollment into the study . In order to manage the total 
trialEnrollment, [COMPANY_009], at its sole discretion, may suspend 
Screening and/or Enrollment at an y 
site or trial -wide at any  time.
6.2. Screening Assessments
6.2.1. Screening Visit
Subjects will be screened within [ADDRESS_747673] (no food or drink, except water) on the evening pri or to the 
Screening 
Visit to ensure an approximate [ADDRESS_747674] prior to the fasting blood sample 
collection the next morning.
The following will be performed and documented during the Screening period :
Obtain written informed consent before initiation of any Screening procedures
Review and record whether the subject has met inclusion and exclusion criteria
Obtain S creening number from IWRS
Obtain medical history  including, but not limited to ,information related to the following: 
type2 diabetes mellitus, NAFLD, and NASH
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 66 22 October 2019Review of historical liver biopsy report (if applicable) obtained within the last 6 months of 
the date of the Screening Visit.
Complete physical examination including vital signs, body  weight, and height
Perform fundus exam with pharmacolog ical pupil -dilation or digital fundus photography  
specified for non- dilated examination (For subjects with ty pe 2 diabetes diagnosed prior to 
the date of the Screening Visit OR on Screening Visit labs (defined as HbA1c ≥6.5% only ). 
If a fundus exam matching this description has been performed within 90 days prior to the 
date of the Screening Visit, the procedure does not need to be repeated, unless there has been 
worsening of visual function since the historical fundus exam in the opi[INVESTIGATOR_261406] r.)
Conduct standard 12 -lead ECG
Perform MRI -PDFF (Historical MRI -
PDFF within 4 weeks of the date of the Screening Visit 
acceptable)
Perform MRE (Historical MRE within 4 weeks of the date of the Screening Visit acceptable)
Perform FibroScan®(Historical FibroScan® within 4 weeks of the date of the Screening Visit 
acceptable)
Collect blood samples for :
Chemistry  and hematology
Coagulation Panel
Insulin and Lipi[INVESTIGATOR_569904] A1c
eGFR
HIV-1, HBV & HCV Serology
Calcitonin 
ELF™ Test 
FibroTest® 
Serum pregnancy  test (only  for female subjects of childbearing potential)
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 67 22 October 2019Collect urine samples for:
Drug screen 
Record an y serious adverse events (SAEs) and all adverse events (AEs) related to protocol 
mandated procedures occurring after signing of the informed consent form.
Record all concomitant medications that the subject has taken within [ADDRESS_747675] administration of study  drug(s), 
record all SAEs, as well as any  adverse events related to protocol- mandated procedures on the 
adverse events case report form eCRF. All other untoward medical occurrences observed during 
the Screening period, including exacerbation or changes in medical histor y are to be captured on 
the medical history  eCRF. See Section 7Adverse Events and Toxicity  Management for 
additional details.
After review of the inclusion and exclusion criteria to confirm eligibility , subjects will return to 
the site for Enrollment and the initiation of Kinetic Biomarkers Cy cle [ADDRESS_747676] (no food or 
drink, except water) on the evening prior to the visit to ensure an approximate [ADDRESS_747677] prior 
to the fasted blood sample collection the next morning. The following assessments will be 
performed and documented at the visit:
Review and record whether the subject has met eligibility  criteria 
Update medical history  if a change has occurred during the S creening period
Symptom driven physical examination 
Record vital signs and body  weight
Collect blood samples (prior to deuterated water administration):
Chemist ry and H ematology  
Coagulation pane l 
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 68 22 October 2019eGFR
Kinetic Biomarkers
Collect urine samples (prior to deuterated water administration) :
Kinetic Biomarkers
Dispense deuterated water. Subjects will drink approximately  [ADDRESS_747678] 30 minutes after for any  side effects.   
Record an y serious adverse events and all adverse events related to protocol m andated 
procedures occurring since the previous visit .
Record all concomitant medications that the subject has taken since the previous visit .
Refer to the laboratory  manual for additional information on the Kinetic biomarkers assessments.
6.3.2. Day -11 and Day 
-7 Visits (± 1 d ay) 
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning.
The following assessments will be performed and documented at each visit:
Collect blood samples:
Kinetic Biomarkers
Collect urine samples:
Kinetic Biomarkers
Subjects will continue to drink deuterated water thr ee times per day  through Day 8. 
Review deuterated water compliance (Day  -7 onl y)
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures since the previous visit .
Record all concomitant medications that the subject has taken since the previous visit .
Refer to the laboratory  manual for additional information on the Kinetic Biomarkers 
assessments.
Protocol GS-US-454-[ADDRESS_747679] (no food or drink, except water) on the evening prior to the 
visit to ensure an approx imate 10-hour fast prior to the fasted blood sample collection the next 
mornin g. The following assessments will be perfon ned and docm nented at the Day 1 Visit prior 
to dosing: 
• Symptom driven phys ical examination 
• R ecord vital signs and body weight 
• QoL quest io1ma ires (CLDQ-NAFLD , EQ-5D) 
Note: It is recommended that the quest ionnaires be completed prior to any study procedures 
being perfonned and prior to the subject seeing a health care provider. 
• Subjects with type [ADDRESS_747680] ion 
with symptom s of hypog lycemia from the Day 1 Visit through the Telephone Follow-Up 
Visit. Plasma glucose values ~70 mg/dL (~3.9 mmol/L) shou ld be reported to the site as a 
hypog lycemic epi[INVESTIGATOR_1865] . Hypo glycemic epi[INVESTIGATOR_569905] . If the hypog lycemic epi[INVESTIGATOR_569906], the event must be reported in 
the eCRF database and to [COMPANY_009] PYE as an SAE . 
• Calculate CP Score once centra l laboratory results are available 
• Collect blood samples for: 
I Chem istry and Hematolo gy 
Coagu lation pane l 
Insulin and Lipid s 
eGFR 
Kinetic Biomark ers 
CONFI DENT IAL Page 69 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 70 22 October 2019Collect urine samples:
Urine pregnancy  test (only  for female subjects of childbearing potential)
Kinetic Biomarkers
Dispense study  drugs, and provide subject with dosing instruction on appropriate dosing and 
administration; subject will take the Day  1 dose of study  drugs on- site
Record an y SAEs and all AEs related to protocol mandated procedures occurring since the 
previous visit
Record al l concomitant medications that the subject has taken since the previous visit
6.4.2. Day 7 (Week 1) Visit (± 3 days)
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. Subjects should also be instructed to hold their dose of study  drug on the morning of 
the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at this visit:
Symptom driven phy sical examination
Record vital signs and body  weight
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
eGFR
Single PK sampling any time during thevisit
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 71 22 October [ZIP_CODE].4.3. Day 28 (Week 4) Visit (± 3 days) 
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The follow ing assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
Insulin and Lipi[INVESTIGATOR_569907]
Collect urine samples for: 
Urine pregnancy  test (only  for female subjects of childbearing potential)
Review study  drug dosing compliance
Dispense study  drugs 
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.4. Day 56 (Week 8) Visit (± 3 days) 
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been compl eted and take their study  drug(s) as 
instructed during the visit.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 72 22 October 2019The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
Insulin and Lipi[INVESTIGATOR_569907]
Collect urine samples for :
Urine pregnancy  test (only  for female subjects of childbearing potential)
Review study  drug dosing compliance
Dispense study  drugs 
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.5. Day 84 (Week 12) Visit (± 3 days) 
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Perform MRI -PDFF
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 73 22 October 2019Perform MRE
Perform FibroScan® 
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
Insulin and Lipi[INVESTIGATOR_569904] A1c
eGFR
FibroTest®
ELF™ Test
Single PK sampling anytimeduring the visit
Collect urine samples for:
Urine pregnancy  test (only  for female subjects of childbearing potential)
 
QoL questionnaires (CLDQ -NAFLD, EQ -5D)
Note: I t is recommended that the questionnaires be completed prior to an y study 
procedures being performed and prior to the subject seeing a health care provider.
Review study  drug dosing compliance
Dispense study  drugs 
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
CCI
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 74 22 October [ZIP_CODE].4.6. Day 112 (Week 16) Visit (± 3 days)
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
eGFR
Collect urine samples for: 
Urine pregnancy  test (only  for female subjects of childbearing potential)
Review study  drug dosing compliance
Dispense study  drugs 
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.7. Day 140 (Week 20) Vis it (± 3 days)  
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instruc ted to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 75 22 October 2019The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
eGFR
Collect urine samples for: 
Urine pregnancy test (only  for female subjects of childbearing potential)
Review study  drug dosing compliance
Dispense study  drugs 
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.8. Day 154 (Week 22) Visit (± 1 day) 
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should a lso be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
Subjects will complete one additional cy cle of Kinetic Biom arkers from Day 154 through 
Day 160 (C ycle 2).
The following assessments will be performed and documented at the visit:
Collect blood samples for (prior to dose of deuterated water administration):
Kinetic Biomarkers 
Collect urine samples (prior to dose o f deuterated water administration) :
Kinetic Biomarkers
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 76 22 October 2019Dispense deuterated water. Subjects will drink approximately  [ADDRESS_747681] 30 minutes after for an y side effects.
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previo us visit
6.4.9. Day 157 (Week 22 Day 2 ) and Day 161 (Week 23) Visit (± 1 day)
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at the visit:
Collect blood samples for:
Kinetic Biomarkers 
Collect urine samples:
Kinetic Biomarkers
Subjects will continue to drink deuterated water three times per day  through Day 160.
Review deuterated water compliance (Day  161 (Week 23) onl y)
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.10. Day 168 (Week 24) / End of Treatment Visit (± 3days)
Subjects should be instructed to fast (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate [ADDRESS_747682] been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 77 22 October 2019Record vital signs and body  weight 
Conduct standard 12 -lead ECG
Perform MRI -PDFF
Perform MRE
Perform FibroScan®
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
Insulin and Lipi[INVESTIGATOR_569904] A1c
eGFR
FibroTest®
ELF™ Test
Kinetic Biomarkers
Collect urine samples for: 
Urine pregnancy  test (only  for female subjects of childbearing potential)
Kinetic Biomarkers
QoL questionnaires ( CLDQ -NAFLD, EQ -5D)
Note: I t is recommended that the questionnaires be completed prior to any  study  
proce dures being performed and prior to the subject seeing a health care provider.
Dispense urine pregnancy  testing kit and provide instructions for home testing atthe 
Telephone Follow -Up visit (only  for female subjects of childbearing potential). 
CCI
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 78 22 October 2019Review study  drug dosing compliance.
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.11. Early Termination (ET) Visit
Subjects prematurel y discontinuing from the study should comple te an ET visit within [ADDRESS_747683] (no food or drink, except water) on the evening prior to the 
visit to ensure an approximate 10- hour fast prior to the fasted blood sample collection the next 
morning. All subjects should also be instructed to hold their dose of study  drug on the morning 
of the visit until all fasting visit procedures have been completed and take their study  drug(s) as 
instructed during the visit.
The following assessments will be performed and documented at the visit:
Symptom driven phy sical examination
Record vital signs and body  weight 
Conduct standard 12 -lead ECG
Perform MRI -PDFF (at the discretion of the investigator)
Perform MRE (at the discretion of the investigator)
Perform FibroScan®(at the discretion of the investigator)
Calculate CP Score once central laboratory  results are available
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel
eGFR
Insulin and Lipi[INVESTIGATOR_805] (at the discretion of the investigator)
Hemoglobin A1c (at the discretion of the investigator)
FibroTest®(at the discretion of the investigator)
ELF™ Test (at the discretion of the investigator)
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 79 22 October 2019Collect urine samples for: 
Urine pregnancy  test (only  for female subjects of childbearing potential)
Dispense urine pregnancy  testing kitand provide instructions for home testing at the 
Telephone Follow -Up visit (only  for female subjects of childbearing potential). 
Review study  drug dosing compliance
Record all concomitant medications that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
6.4.12. Unscheduled Visits
Additional unscheduled assessments may  be performed at the discretion of the investigator. At a 
minimum, the following will be performed and documented.
Symptom driven PE
Record vital signs, and body  weight
Collect blood samples for:
Chemistry  and Hematology
Coagulation panel 
Record all concomitant mediations that the subject has taken since the previous visit
Record an y SAEs / AEs since the previous visit
If the Unscheduled visit is performed for the sole purpose of the distribution of study  drug, 
theassessments noted above do not need to be performed .
6.5. Posttreatment Assessments
6.5.1. Telephone Follow -Up Visit (± 3 da ys) 
Subjects that received at least one dose of stud y drug will be contact[CONTACT_5365] a Telephone 
Follow -Up Visit [ADDRESS_747684] dose of study  drugs. 
The following assessments during the Telephone F ollow -Up visit :
Record all concomitant medications that the subject has taken since previous study  visit
CCI
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 80 22 October 2019Record an y SAEs / AEs since the previous visit
Record subject reported results of the urine pregnancy  test ( only for female subjects of 
childbearing potential).
At the discretion of the inve stigator, an unscheduled visit may  be completed if the subject reports 
abnormal or concerning symptoms.
Table 6-1. Visit Windows
Study Visit Window
Screening Visit ≤ 2 w eeks prior to Day -14, w indow  begins with the signing of the 
informed consent*
Day -[ADDRESS_747685] dose of deuterated water
Day -11& Day -7 ± [ADDRESS_747686] dose of study drugs. All 
on-treatment study visits are calculated based on the Day 1 date
Day 7 (W eek 1), Day 28 (Week 4), 
Day 56(Wee k 8), Day 84 (Week 12), 
Day 112(Week 16) & Day 140 (Week 20)± 3 days
Day 154 (Week 22), 
Day 157(Week 22Day 2) & 
Day 161(Week 23)± 1 day
Day 168 (Week 24/EOT) ± [ADDRESS_747687] dose of study drug or pre -treatment 
deuterated w ater
Telephone Follow -Up Visit ± 3 days
* The Screening period also may  be extended under special circumstances with the explicit 
approval of [COMPANY_009] Sciences, Inc .
6.6. Criteria for Discontinuation of Study Treatment
Study  drug may be discontinued in the following instances:
Simultaneous participation in another clinical trial of an approved or non -approved 
investigational medicinal product
Diagnosis of acute pancreatitis
Diagnosis of medullary  thyroid 
carcinoma
Surgical treatment for obesity
Treatment with other GLP -1 receptor agonists other than semaglutide 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 81 22 October 2019Subject progression to decompensated cirrhosis, as defined b y any of the following:
Clinically  apparent ascites requiring treatment
HE of Grade 2 or above (according to the West Haven criteria inAppendix 5) requiring 
treatment .
Portal hy pertension
-related upper gastrointestinal bleeding identif ied b y endoscopy and 
requiring hospi[INVESTIGATOR_059], including events of bleeding from esophageal varices, gastric 
varices, and portal h ypertensive gastropath y.
CP score ≥ [ADDRESS_747688] two weeks apart unless due to an alternate 
etiolo gy (e.g., therapeutic anticoagulation); refer to Section 7.6.3.
Liver transplantation 
Subject develops an SAE consisting of a serious hypersensitivity  reaction to study  drug
Intercurrent illness that would, in the judgment of the Investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study  dosing a t the discretion of the Investigator, in consultation with the 
Medical Monitor .
Unacceptable toxicity  or toxicity  that, in the judgment of the Investigator, compromises the 
ability  to continue study -
specific procedures or is considered to not be in the sub ject’s best 
interest .
Subject or Investigator request to discontinue for any  reason.
Significant subject noncompliance .
Significant protocol violation that impacts subject safet y
.
Pregnancy  during the study ; refer to Appendix 3
Discontinuation of the study  at the request of [COMPANY_009], a regulatory  agency , or an IRB.
6.7. Assessments for Premature Discontinuatio nfrom Study
It is recommended that subjects who discon tinue study  drugs be encouraged to stay  on study  and 
compl ete the scheduled assessments. Subjects prematurely  discon tinuing from the study  
(eg,dueto subject withdrawing consent, investigator decision, or sponsor decision) should 
complete an ET visit with in [ADDRESS_747689] dose (refer to Section 6.4.10 ). Discussion with 
the Medical Monitor prior to discontinuation of study  drug or study  is recommended
If a subject is lost to follow
-up, survival data may  be gathered from public records such as 
government census or death records (if permitted by  [CONTACT_427]) prior to the completion of 
the study .
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 82 22 October [ZIP_CODE].8. Interruption of Study Drug
If dosing is interrupted (i.e., as a result of an AE), the subject must stop dosing of all stud y drugs. 
Every  attempt should be made to keep the subject in the study  and continue to perform the 
required stud y-related procedures. Discussion with the Medical Monitor is recommended. If this 
is not possible or acceptable to the s ubject or Investigator, the subject may be withdrawn from 
the study . 
6.9. End of Study
End of study  is considered to be completion of the Telephone Follow -Up visit.
6.10. Description of Assessments
6.10.1. Clinical Laboratory Analytes
Fasting is required prior to all study  visits.
Chemistry :
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, alkaline 
phosphatase (ALP), bicarbonate, blood urea nitrogen (BUN),) creatine kinase (CPK), calcium, 
chloride, creatinine, glucose, magnesium, phosphorus, potassium, sodium, total and direct 
bilirubin, total protein, uric acid, and gamma -glutamy l transferase (GGT). 
Hematology :
Hematocrit (Hct), hemoglobin (Hb), platelet count, red blood cell count (RBC), white blood cell 
count (WBC) with differential (absol ute and percentage) including l ymphoc ytes, monoc ytes, 
neutrophils, eosinophils, basophils, and mean corpuscular volume (MCV ).
Coagulation Panel:
INR, prothrombin time (PT), partial thromboplastin time (PTT).
Insulin and lipi[INVESTIGATOR_805]:
Insulin homeostasis model assessment of Insulin resistance (HOMA -IR, based on fasting glucose 
and insulin), C- peptide and lipid panel.
Pregnancy  Tests:
Serum β -hCG or urine β -hCG (if positive, requires immediate confirmation with serum β- hCG).
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
Additional Tests: Final 
Amendme nt2 
HIV-1 (re flex to HIV-1 RNA ), HBV (HBsAg), HCV (reflex to HCV RNA ) serology, urine drug 
screen (for amph etamines, coca ine, methadon e, opi[INVESTIGATOR_858]), eGFR as calculated by [CONTACT_86605] , HbAlc , 
calcitonin , genomic s ampl e collection, ELfT M Test, and FibroTest® . 
Phannacokin etic (PK) Assess ments: 
Single PK samples may also be u sed to measure protein-binding of study drug(s) and/or its 
metabolites, as applicabl e. 
Biomark er Tests: 
Kinetic Bi omark er Assess ments 
6.10.2. Creatinine Clearance /eGFR 
eGFR is estimated by [CONTACT_569948] e calculated by [CONTACT_569949] (MDRD ) Stud y equation: 
eGFR (mL/min/1.7 3 m2) 175 x Serum Creainine- 1.154 x (Age) --0-203 x (1.212 if 
African Ame rican ) x (0. 742 if female) 
Serum creatinine in umol/L should be rom1d ed to zero decimal places and converted to mg/dL by 
[CONTACT_195914] 0.[ZIP_CODE] prior to applying the fonnu la. Creatinine in m g/dL is rom1d ed to 
2 deci mal places prior to applying fonnu la. 
6.10.3. Child-Pu gh (CP) Score 
Child Pugh score is u sed to assess the prognosis of chronic liver disease, primarily cirrhosis. 
CP scores will be calculated by [CONTACT_569950]. 
CON FIDENTIAL Page [ADDRESS_747690] is lethargic, may 
(HE) not on any treatment for have moderate confusion 
hepatic encephalopathy 
Subject is receiving medical 
Ascites 
No ascites and not on 
treatment for ascites 
Bilirubin (mg/dL) < 2 
Albumin (g/dL) > 3.5 
INR < 1.7 
CP is obta ined by [CONTACT_199615]. 
CP class: 
A 5 6 points 
B 7 9 points 
C IO 15 points therapy for HE 
Mild /Moderate 
Cross sectional imaging 
showing ascites 
Abdominal distension 
Med ication for ascites 
2-3 
2.8-3.5 
1.7-2.3 3 
Medication-Refractorl'. 
Marked confusion /incoherent, 
rousable but sleepi[INVESTIGATOR_569908] 
(diuretic-refractor:i} 
Visible clinically 
> 3 
< 2.8 
> 2.3 
Records of concom itant medications for ascites and HE will be collected in the eCRF . 
6.10.4. MRE and MRI-PDFF 
The sites will perfonn liver stiffness assessments by [CONTACT_232761] (shear wave 60 Hz) and MRI -PDFF at 
the Screen ing Visi t, Day 84 (Week 12) and Day 168 (Week 24). For ET visi ts, the assess ments 
are perfonned at the discretion of the investigator. The assessments can occur seque ntiall y. 
At least 4 hours fasting is reco1mnended prior to all MR assessments . The MRE and MRI-PDFF 
sc · ET visi ts 
Please refer to the MR Proc edures Manual for instructions on MRE and MRI-PDF F 
measure ments. 
CONFI DENT IAL Page 84 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 85 22 October [ZIP_CODE].10.5. FibroScan®
FibroScan® examinations will be performed at the Screening Visit, Day 84 (Week 12) and 
Day 168 (Week 24) and median liver stiffnes s in kilopascals (kPa), interquartile range/median 
value (IQR/M), and success rate (number of valid shots/total number of shots) will be recorded. 
Where available, the median CAP and the interquartile range of CAP values will be recorded 
from FibroScan®examinations. For ET visits, the assessments are performed at the discretion of 
the investigator.
For individual subjects, the same device mus t be used for all assessments. Probe size should be 
determined based on the machine probe size recommendation at the Screening assessment. The 
same probe size should then be used at all subsequent assessments. If the machine being used 
does not recommend a probe size, an XL probe should be used at all exams if available. If an XL 
probe is not available and/or a valid re sult cannot be obtained, an examination with the M probe 
must be performed and the result recorded. At least 2-3hours fasting is recommended prior to all 
elastograph y assessments.
6.10.6. Electrocardiogram
Standard 12
-lead electrocardiogram (ECG) assessments will be performed at Screening ,
Day 168(Week 24) and the Earl y Termination (ET) visits. The I nvestigator will review the 
ECGs for an y clinicall y significant abnormalities to ensure subject safet y. Abnor mal ECG 
findings that are considered clinically  significant by  [CONTACT_569951].
6.10.7. Medical History
Medical history , including details regarding illnesses and allergies, date (s) of onset, and whether 
condition(s) is currentl y ongoing, and medication history  will be collected on all subjects during 
the S creening period .
6.10.8. Physical Examination
A complete ph ysical examination must include source documentation of general appearance, and 
the following bod y systems: head, neck, and th yroid; ey es, ears, nose, throat, mouth, and tongue; 
chest (excluding breasts); respi[INVESTIGATOR_696] ; cardiovascular; ly mph nodes; abdomen; skin, hair, nails; 
musculoskeletal; neurological. Height, vital signs, and body  weight will also be collected.
The focus of a s ymptom driven PE will be determined by  [CONTACT_569952] s. For example, if a subject complains of a cough, a lung exam should be performed. If
consistent with pneumonia (rales/crackles on exam) then an AE would be documented.
Height and body  weight will be collected at specified time points.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 86 22 October [ZIP_CODE].10.9. Fundus Examination
For subjects with t ype 2 diabetes ( from medical history  or from Screening Hemoglobin A1c 
≥6.5%) , a fundus exam will be performed at Screening. Fundus examinations require 
pharmacological dilation of both pupi[INVESTIGATOR_569909] a digital fundus photograph y camera 
specified for non- dilated examination . Results of the fundus exam will be evaluated b y the
investigator and the investigator evaluation must be documented either on the fundus 
examination result report or in the subject’s medical record. 
The investigator or medically  qualified delegate must sign, date and interpret the fundus 
examination by  [CONTACT_334673]:
Normal
Abnormal
Was the result clinically  significant? (Yes/No)
If a fundus examination matching this description has been performed within [ADDRESS_747691] be available prior to Enrollment (Day  
-14). 
If the dilated fundus examination is performed before the subject has s igned the informed 
consent form, it must be documented in the medical records that the reason for performing the 
procedure was not related to this trial.
6.10.10. Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, and 
temperature.
Blood pressure will be measured using the following standardized process:
Subject should sit for ≥ 5 minutes with feet flat on the floor and measurement arm supported 
so that the midpoint of the manometer cuff is at heart level;
Use a mercury  sphygmomanometer or automatic blood pressure device with an appropriately  
sized cuff with the bladder centered over the brachial artery ;
Measure and record the blood pressure to the nearest [ADDRESS_747692] at Screening. Urine
pregnancy  testing will occur at Day  1 (prior to dosing) , Week 4, Week 8, Week 12, Week 16, 
Week 20 and Week 24 (EOT) or ET visits. All females of childbearing potential that received at 
least one dose of stud y drug will be dispensed a urine pregnancy  testing kit at the
Week 24(EOT) or ET visit for home testing at the Telephone Follow -
Upvisit. At the Telephone 
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. Final 
Amend ment2 
Follow-Up visit, subjects will be requested to report the result of the urine pregnancy tests. In the 
event of a posit ive urine pregnancy result, subjects will be instructed to stop study drug 
iimn ediately (if applicable) and return to the clinic as soon as poss ible for a serum pregnancy 
test. 
6.10.12. Health Related Quality of Life (HRQoL) Measures 
It is recommended that these quest io1maires be comp leted prior to the clinical and laboratory 
assessments . The subject shou ld read the quest io1maires by [CONTACT_569953]/herse lf and record the 
answers by [CONTACT_199616]/herse lf. 
6.10.12 .1. Chronic Liver Disease Questionnaire-Nonalcoho lic Fatty Liver Disease 
(CLDQ -NAF LD) 
The CLDQ-NAFLD asks quest ions related to liver disease and spec ifically NAFLD, to measure 
health related quality of life in subjects with chron ic liver disease . 
6.10.12 .2. EuroQo l Five Dim ensions (EQ-5D ) 
The EQ-5D questio1ma ire is a standard measure of health status deve loped by [CONTACT_569954] l 
Group to provide a simple, gener ic measure of health for clinical and econo mical appra isal {The 
EuroQol Group 1990 }. The EQ-5D is not disease spec ific and has been validated in nmn erous 
health states . The tool cons ists of the EQ-5D descript ive syste m and the EQ Visual Analog Scale 
(VAS) . The descript ive part compr ises 5 dimensions (mobility , self-care, usua l activities, 
pain/discomfort , and anxiety/depress ion). Each of these 5 dimensions has 5 levels (no prob lem, 
slight prob lems, mod erate problems, severe prob lems and unab le to). Results for each of the 
[ADDRESS_747693]'s health state . The VAS 
records the subject's health on a 0-100 1mn VAS scale, with 0 indicating "the worst health you 
can imagine" and 100 indicating "the best health you can imagine". -
-
CONFI DENT IAL Page 87 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 88 22 October [ZIP_CODE]. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and
/orunintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered relate d to 
the medicinal product. AEs may  also include pre -or posttreatment complications that occur as a 
result of protocol specified procedures or special situations (Section 7.7). Preexisting events that 
increase in severit y or change in nature during or as a consequence of participation in the clinical 
study  will also be considered AEs.
An AE does not include the fol
lowing:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities prese nt or detected before the 
Screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred ( eg.hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it was more severe.)
In-patient hospi[INVESTIGATOR_569910] -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 89 22 October 2019Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_82221]. Medical and 
scientific judgment must be exercised to determine whether such an event is a r eportable 
under expedited reporting rules. 
Examples of medically  important events include:
Intensive treatment in an emergency  room or at home for allergic bronchospasm;
Blood dy scrasias or convulsions that do not result in hospi[INVESTIGATOR_059];  
Development of drug dependency  or drug abuse. 
A hy poglycemic epi[INVESTIGATOR_569911] a criteria above or it requires the 
assistance of another person to correct (e.g., to administer carboh ydrate).
For the avoidance of doubt, infections resulting from contaminated medicinal product will be 
considered a medicall y important event and reported as a SAE .
[IP_ADDRESS]. Events of Special Interest 
Hypoglycemic epi[INVESTIGATOR_569912]. For subjects without T2D, 
epi[INVESTIGATOR_569913] 7.Subjects with T2D must be instructed 
to measure their blood glucose in connection with sy mptoms of hy pogly cemia. Plasma glucose 
values 
≤70 mg/dL (≤3.9 mmol/L) should be reported as a h ypog lycemic epi[INVESTIGATOR_1865]. This and other 
relevant clinical data must be reported on a h ypogly cemic epi[INVESTIGATOR_569914]. If the 
hypoglycemic epi[INVESTIGATOR_569906], the event must be reported in the eCRF 
database and to [COMPANY_009] PVE as an SAE.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified sub-investigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessment s.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 90 22 October [ZIP_CODE].2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified sub-investigator is responsible for assessing the relationship to 
study  drug therapy  using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  drug . For 
SAEs, an alternative causality  must be provided (eg, pre -existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that th e event may  have been caused by [CONTACT_10853].
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship of an AE or SAE to study  procedures (eg, invasive procedures such as 
venipuncture or biops y)or study  devices (eg, PDS290 pen- injector) should be assessed using
clinical judgement describing the event as either unrelated (No) or related (Yes) consistent with 
the following definitions:
No: Evidence exists that the adverse event has an etiology  other than the stu dy procedure or 
device.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venipuncture) or 
device.
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, 4, or 5 according to the Common 
Terminology  Criteria for Adverse Events (CTCAE), which can be found in the Site Operations 
Manual and Appendix 4.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the
clinical severit y in the context of the underlying conditions; this may or may not be in agreement
with the grading of the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted.
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For
example, a headache ma y be severe in intensity , but would not be classified as serious unless it
met one of the criteria for serious events listed above.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 91 22 October [ZIP_CODE].3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009] 
Requirements f or collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form eCRF: all SAEs and adverse events related to 
protocol -mandated proce dures.
Adverse Events
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
through [ADDRESS_747694] consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required posttreatment Follow -Up period, must be reported to the 
eCRF database and Gilea d Pharmacovigilance and Epi[INVESTIGATOR_623]  (PVE) as instructed. This also 
includes an y SAEs resulting from protocol
-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the posttreatment Follow -Up visit but withi n [ADDRESS_747695] dose of study  drug regardless of causality should also be reported. 
Investigators are not obligated to activel y seek SAEs after 
the protocol defined Follow -Up 
period; h owever, if the investigator learns of any  SAEs that occur after study  participation has 
concluded and the event is deemed relevant to the use of study  drug or device , he/she should 
promptly  document and report the event to [COMPANY_009] Pharmacovigilance and Epi[INVESTIGATOR_623]  (PVE) .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
At the time of study  start, SAEs may  be reported using a paper serious adverse event 
reporting form. During the study  conduct, sites may  transition to an electronic SAE (eSAE) 
system. 
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
Electro nic Serious Adverse Event ( eSAE) Report ing Process Final 
Amendment2 
• Si te perso1me l record all SAE data in the eCRF database and from there trans mit the SAE 
infon nation to [COMPANY_009] PYE wi thin [ADDRESS_747696] igator's know ledge of the event. 
Detailed instruct ions can be fom1d in the eCRF completion guide lines. 
• If for any reason it is not poss ible to record the SAE infonnation electron ically, ie, the eCRF 
database is not funct ioning, record the SAE on the paper serious adverse event report ing 
fonn and submit within 24 hours to: 
[COMPANY_009] Sciences PYE: Fax: [COMPANY_003] 
Ema il: PPU 
• As soon as it is poss ible to do so, any SAE reported via paper must be transcr ibed into the 
eCRF Database according to instruct ions in the eCRF completion guidelines. 
• If an SAE has been reported via a paper fonn because the eCRF database has been locked, no 
further action is necessary . 
• For fatal or life-threaten ing events, copi[INVESTIGATOR_569915], autopsy reports, and other 
documents are also to be subm itted by e-mail or fax when requested and app licable. 
Transm ission of such documents shou ld occur without persona l subject identification, 
maintaining the traceab ility of a docm nent to the subject ident ifiers. 
• Additional infon nation may be requested to ensure the timely comp letion of accurate safety 
reports . 
• Any medications necessary for treatment of the SAE must be recorded onto the concom itant 
medication section of the subject's eCRF and the event descr iption section of the SAE fonn. 
7.4. [COMPANY_009] Reportin g Requirements 
Depend ing on relevant local legislation or regu lations, including the applicable US FDA Code of 
Federa l Regu lations, [COMPANY_009] may be required to exped ite to worldwide regulatory agenc ies 
reports of SAEs, serious adverse drug react ions (SADRs), or suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) . 
Assessment of expectedness for SAEs will be deten nined by [CONTACT_569955]'s brochure or relevant local label as applicable. 
All invest igators will receive a safety letter notifying them of relevant S[LOCATION_003]R reports assoc iated 
with any study drug . The invest igator shou ld notify the IRB of SU SAR reports as soon as is 
practica l, where this is requ ired by [CONTACT_569956], and in accordance with the local 
institutional policy. 
CONFIDENT IAL Page 92 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 93 22 October [ZIP_CODE].5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorde d as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_747697] the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , 
please refer to Sections 7.1and7.6.
Severity  should be recorded and graded according to the CTCAE Toxicity Grading Scale 
(Appendix 4). For AEs associated with laboratory abnormalities, the event should be graded on 
basis of the clinical severity  in the context of the underly ing conditions; this may  or may  not be 
in agreeme nt with the grading of the laboratory  abnormality .
7.6. Toxicity Management 
7.6.1. Observation for Drug Induced Liver Injury (DILI)
At baseline, some subjects may  have liver biochemistry  levels above the upper limit of the 
normal range ( ULN )
. Baseline values for live r tests (AL T, AST, and total bilirubin) will be 
determined b y averaging the values obtained between and including Screening and Enrollment 
(Day -14) . Please refer to the Covance Laboratory  Manual or individual subject Covance 
laboratory  report for gender a nd age specific reference ranges.
Unless the clinical context points towards an apparent etiology, on- treatment elevations of ALT 
and/or AST should be confirme d with repeat testing within [ADDRESS_747698] be placed into close 
observation (as described below).
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 94 22 October 2019Figure 7-1. On-Treatment ALT/AST Monitoring Requiring Close Observation
7.6.2. Close Observation
Close observation includes:
Repeating liver biochemistries (ALT, AST, ALP, GGT, total bilirubin, I NR) and obtaining a 
CPK level within 72 hours of results
Obtaining a more detailed history  of symptoms and prior or concurrent disease
Obtaining a history
 of concomitant drug use (includ ing nonprescription medications and 
herbal and dietary  supplement preparations), alcohol use, recreational drug use, and special 
diets
Obtaining a history  of exposure to environmental chemical agents
Ruling out other causes of liver disease as needed (obtain viral hepatitis panel, imaging for 
evaluation of biliary  tract disease, etc. if required in the opi[INVESTIGATOR_689])
Continue to monitor liver biochemistries at least twice weekl y. Frequency can decrease to 
once a week or less if abnormalit ies stabilize or study  drugs have been discontinued and the 
subject is asy mptomatic
     
       
       
  
     
    
     
       
    
     
    
 
      
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 95 22 October 2019During a period of close observation for DILI, study  drugs can be continued, if desired, at the 
discretion of both the Medical Monitor and Investigator.
If on -treatment elevations of ALT and/or AST exceed the values shown in Figure 7-2, are 
confir med on repeat testing within 
[ADDRESS_747699] results. For AEs associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory abnormality . 
Any questions regarding toxicity  management should be directed to the Medical Monitor.
7.6.3. CP Score
If a subject has an increase in their CP score to ≥ 7, this should be confirmed with repeat testing 
within [ADDRESS_747700] should be placed in close observation described above, unless an alternate etiology  
(eg, therapeutic anticoagulation) is identified. If the CP remains ≥ [ADDRESS_747701] baseline dy slipi[INVESTIGATOR_035], some subjects may  
experience further elevations in their trigl ycerides. Figure 7-3describes the recommended 
monitoring and intervention strategy  for subjects that meet the criteria for on
-treatment 
hypertrigly ceridemia of Grade 3 or 4 ( ≥ 500 mg/dL).
Figure 7-3. Algorithm for Monitoring and Treatment of Hypertriglyceridemia
     
   
   
    
   
    
       
    
    
     
    
      
         
        
      
      
       
 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 97 22 October [ZIP_CODE].6.5. Pruritus Management
The development or worsening of pruritus during the study  is a consideration for patients with 
liver disease. Management of pruritus may include nonpharma cologic interventions 
(eg,skin moisturization, minimized heat exposure, avoidance of skin irritants, scratch reduction), 
oral antihistamines, and/or bile acid sequestrants. Bile acid sequest rants must be taken more than 
4hours befor e or after the study  drug dosing, as described in Table 5-3. Administration of study  
drugs with a light -fat meal may  be beneficial. If interruption of study  drugs is deemed necessary , 
all study  drugs must be held (see Section 6.9). There is no option for dose reduction. 
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports include all 
reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,occupational exposure with an AE, and 
pregnancy  reports regardless of an associated AE , and AE in an infant following exposure from 
breastfeeding.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or c onsumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per ad ministration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be establishe d only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additio nal dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Occupational exposure is defined as exposure to a medicinal product as a result of one’s 
professional or non -professional occupation.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 98 22 October [ZIP_CODE].7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  drug and throu ghout the stud y, including the post study drug Follow -Up 
period, to [COMPANY_009] PVE using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .Reports should be sent directl y to [COMPANY_009] PVE at 
faxnumber or email 
Refer to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within [ADDRESS_747702] in formation is as follows: 
Email: and Fax:  
Pregnancies of female partners of male stud y subjects exposed to [COMPANY_009] or other study  drugs 
must also be reported and relevant information should be submitted to [COMPANY_009] PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Mon itoring of the pregnant partner 
should continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after 
the study  has been completed, the outcome should be reported directl y to 
[COMPANY_009] PVE ,faxnumber  or email 
Refer to Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] PVE within [ADDRESS_747703] of situations that involve study  drug and/or [COMPANY_009] concomitant 
medications
, but do not apply to non-[COMPANY_009] concomitant medications. 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 99 22 October 2019Special situations involving non-[COMPANY_009] concomitant medications does not need to be reported on
the special situ ations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by
 [CONTACT_10857] “ misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
Protocol GS-US-454-[ADDRESS_747704] ive of this study is as follows: 
• To evaluate the safety and tolerability of study drug(s) in subjects with NASH 
I 
I 
I 
I 
I 
I 
8.1.2. Primary Endpoint Final 
Amendment2 
The primary endpo int is the safety and tolerability of study drug(s) in subjects with NASH . -
I 
I 
I 
I 
CONFIDENT IAL Page 100 22 October 2019 
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
I 
I 
I 
I 
I 
I 
8.2. 
8.2.1. 
[IP_ADDRESS]. Analysis Conventions 
Analysis Sets 
Efficacy Final 
Amend ment2 
The primary analysis set for efficacy analyses will be the Full Analysis Set (FAS) which includes 
all subjects who were randomized and received at least one dose of study drug. 
Subjects who receive study drugs other than that to which they were assigned w ill be analyzed 
accor ding to the treatment group to which they were randomized. 
[IP_ADDRESS]. Safety 
The primary analysis set for safety analyses will include a ll subjects who received at least one 
dose of study drug. Treatment-emergent data will be analyzed and defined as data collected from 
the first dose of study drug through the d ate of last dose of study drug plus 30 days. Subjects who 
received study drug other than that to which they were assigned w ill be analyzed accor ding to the 
study drug received. 
[IP_ADDRESS].1. Phannacokin etics 
The PK analysis set will include a ll randomized subjects who took at least one dose of study 
drug and have at least [ADDRESS_747705] ing to the treatment received; otherw ise, if the subject is not 
dosed, then they will be excluded from the smmnary. If safety laboratory results for a subject are 
missing for any reason at a time point, the subject will be excluded from the calculation of 
smmna ry statistics for that time point. If the subject is missing a pre-dose value, then the subject 
will be excluded from the calcu lation of smmna ry statistics for the pre-dose value and the change 
from pre-dose values. 
Values for missing safety laboratory data and vital signs will not be imputed; however, a missing 
baseline result will be replaced with a Screen ing result, if available. If no pre-treatment 
laboratory value is available, the base line value will be assumed to be nonna l (ie, no grade 
[Grade OJ) for the smmna ry of graded laboratory abnonna lities. 
8.4. Demographic Data and Baseline Characteristics 
Demograp hic and base line measure ments will be smmnariz ed using standard descr iptive 
methods by [CONTACT_55690]. Demograph ic smmnari es will include sex, race, 
ethnicit y, and age. 
Baseline character istics smmna ry will include body weight, height, body mass index, presence or 
absence of type 2 diabetes, and other disease character istics as necessary . 
8.5. Efficacy Analysis 
The biol ogical activity of study drug(s) will be evaluated using radiologic endpo ints and 
biomarker variables. Because efficacy endpoints will be evaluated for exploratory purpose, 
fonna l statistica l compar isons will not be made for these endpo ints. Instead, descr iptive statistics 
(n, mean, SD, median, Ql, Q3, minimum , and maximum) will be prov ided by [CONTACT_1570] . -
CONFI DENT IAL Page [ADDRESS_747706] dose of study drug administration (up to and 
including [ADDRESS_747707] dose of study  drug) will be summarized by  [CONTACT_569957] y drug received.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug 
administration eCRF page . Exposure data will be summarized by  [CONTACT_1570]. 
8.6.2. Adverse Events
Clinical and laboratory  adverse events will
be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database. Adverse eve nt severity  will be graded using CTCAE .
Events will be summarized on the basis of the date of onset for the event. Treatment -emergent 
adverse event s(TEAEs) are defined as 1 or both of the following :
Any AEs with an onset date on or after the study  drug st art date and no later than 30 day s
after permanent discontinuation of study  drug.
Any AEs leading to premature discontinuation of study  drug.
Summaries (number and percentage of subjects) of TEAEs by [CONTACT_2946] ( HLT,) and PT will be 
provided b y treatment group
. Treatment -emergent AEs will also be summarized by  [CONTACT_569958] . In addition, TEAEs leading to premature discontinuation of study  
drug will be summarized.
All AEs reported during the study  will be presented in data listings with TE AE indicated
(yes/no).
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and 
maximum) by  [CONTACT_569959].
Graded laboratory  abnormalities will be defined using the grading scheme in the CTCAE .
Protocol GS-US-454-[ADDRESS_747708] dose of study drug plus 30 days, will be smmnariz ed by [CONTACT_1570] . If base line data are 
missing, then any graded abnonna lity (ie, at least a Grade 1) will be cons idered treatment 
emergent. 
8.7. Pharmacokinetic Analysis 
Plasma concentrat ions of study drug(s) and relevant metabo lites, as applicable, will be listed. 
8.7.1. Other Safety Evaluations 
Vital sign measure ments and 12-lead ECG data will be smmnariz ed by [CONTACT_447423]. 
8.8. Biomarker Analysis 
The kinetic biomarkers will be analyzed to evaluate the PD effects of study drug(s) . The 
assessment will involve the analysis of DNL values; spec ifically, the change (abso lute and 
relative) from base line between the post-dose and pre-dose deuterated water loading periods. 
8.9. Sample Size 
Due to the exploratory nature of this study, the sample size was not detenn ined by [CONTACT_569960] l 
power calculation. The number of subjects in each treatment group was decided based on clinical 
exper ience with other similar proof of concept studies. 
8.10. Data Monitoring Committee 
An interna l [COMPANY_009] data monitorin g c01mn ittee (DMC ) will review the progress of the study and 
perfonn interim reviews of safety data. The DMC will be notified of any case of suspected DILi 
by [CONTACT_1689]. The DMC will prov ide reco1mnendations whether the nature, 
frequency, and sever ity of adverse effects assoc iated with study treatment warrant the early 
tennination of the study in the best interests of the partici pants, whether the study should 
continue as planned, or the study shou ld continue with modification s. The DMC 's spec ific 
activities will be defined by a mutuall y agreed upon charter, which will define the DMC 's 
membership, conduct, and meeting schedu le. 
CON FIDENT IAL Page 104 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 105 22 October [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The Investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Conference on Harmonization (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The Investigator will ensure adherence t o the basic principles of Good Clinical Practice, as 
outlined in 21 Code of Federal Regulations (CFR) 312, subpart D, “Responsibilities of Sponsors 
and Investigators,” [ADDRESS_747709] be provided prior to 
the I
nvestigator’s (and any  subinvestigator’s) participation in the study . The I nvestigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_747710] be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study. The investigator and subinvestigator agree to notify  [COMPANY_009] of any  
change in reportable interests durin g the study  and for [ADDRESS_747711] (IRB) Review and Approval
The investigator (or sponsor as appr opriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed 
consent) to an IRB . The investigator will not begin an y stud y subject activities until 
approval from the IRB has been documented and provided as a letter to the investigator.
Protocol GS -US-454-[ADDRESS_747712]’s legall y authorized representative , the pers on conducting the consent discussion, and an 
impartial witness 
(if required by  [CONTACT_5277] ). The consent form will inform subjects 
about pharmacogenomic testing and sample retention, and their right to receive clinicall y 
relevant pharmacogenomic ana lysis results.
9.1.5. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  an identification code and an y other 
unique identifier (s) as allowed by [CONTACT_1769] (such as y ear of birth) will be recorded on an y form 
or biological sample submitted to the Sponsor, IRBor laboratory . Laboratory  specimens must be 
labeled in such a way  as to protect subject identity  while allowing the results to be recorded to
the proper subject. Refer to specific laboratory  instructions . NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in acc ordance with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator 
brochure, this protocol, eCRF s, the study  drug , and any  other study  information, 
remain the sole and exclusive property of [COMPANY_009] during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written c onsent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.6. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigato r’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, IRB 
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae an d authorization forms, and other appropriate documents and correspondence.
Protocol GS -US-454-[ADDRESS_747713]:
Subject identification (name, date of birth, gender);
Docume ntation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled ;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Date sof all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as r equired b y the protocol;
Start and end date (including dose reg imen) of study  drug , including dates of dispensing and 
return;
Record of all adverse events and other safety  parameters (start and end dat e, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at lea st 2years or 
according t o local laws, whichever is lon ger, after the last approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_747714] been received. Subsequent to data entry , a study  monitor will perform source data 
verif ication within the electronic data capture ( EDC )system. Original entries as well as any  
changes to data fields will be stored in the audit trail of the sy stem. Prior to database lock (or an y 
interim time points as described in the clinical data management plan), the investigator will use 
his/her log in credentials to confirm that the forms have been reviewed , and that the entries 
accuratel y reflect the information in the source documents. The eCRF capture the data required 
per the protocol sche dule of events and procedures. System -generated or manual queries will be 
issued to the investigative site staff as d ata discrepancies are identified b y the monitor or internal 
[COMPANY_009] staff, who routinely  review the data for completeness , correctness, and consistency .The 
site coordinator is responsible for responding to the queries in a timel y manner, within the 
system, either b y confirming the data as correct or updating the original entry , and providing the 
reason for the update (e.g. data entry  error). At the conclusion of the trial, [COMPANY_009] will provide the 
site with a read-onl y archive cop y of the data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the records retention r equirements outlined in Section 9.1.[ADDRESS_747715] 
operating procedure ( SOP)for drug destruction as determined b y [COMPANY_009], the site may destro y 
used (empt y or partially empty) an d unused study drug supplies in accordance with that site’s 
approved SOP. A cop y of the site’s approved SOP will be obtained for central files. If study  drug
is destroy ed on site, the investigator must maintain accurate records for all study  drug destro yed. 
Records must show the identification and quantity  of each unit destroy ed, the method of 
destruction, and the person who disposed of the study  drug . Upon study  completion, copi[INVESTIGATOR_569916] . Another copy will be returned to 
[COMPANY_009]. 
If the site does not have an appropriate SOP for drug destruction, used and unused study  drug
supplies are to be sent to the designated disposal facility  for eventual destruction. The study  
monitor will provide i nstructions for return.
The study  monitor will review study  drug supplies and associated records at periodic intervals.
9.1.9. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monit ors, to IRBs, or to regulatory  authorit y or health authority 
inspectors.
Protocol GS -US-454-[ADDRESS_747716] submit a ll protocol modifications to the IRB in 
accordance with local requirements and receive documented IRB approval before modifications 
can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared .[COMPANY_009] will ensure that the report meets the 
standards set out in the ICH Guideline for Structure an d Content of Clinical Study Reports 
(ICHE3). Note that an abbreviated report may be prepared in certain cases. 
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the followin g conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed by [CONTACT_337370], manuscript, or presentation form or the stud y has been completed at 
all study  sites for at least 2 y ears
The investigator will submit to [COMPANY_009] any  proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 day s before submission of 
the publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.5).
The investigator will comply  with [COMPANY_009]’s request to delete refe rences to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 110 22 October [ZIP_CODE].3. Joint Investigator/Spo nsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendan ce at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies an y 
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to In formation for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for ro utine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected 
through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the [COMPANY_009] medical monitor immediately . The investigat or agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to ter minate the study at any  time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs.In terminating the study , [COMPANY_009] and the investigator will assure 
that adequate conside ration is given to the protection of the subjects’ interests.
Protocol GS -US-454-[ADDRESS_747717] 2012;18 (1):29 -37.
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safet y and 
efficacy  in patients with non -
alcoholic steatohepatitis (LEAN): a multicentre, 
double -blind, randomised, placebo- controlled phase 2 study . Lancet 2016;387 
([ZIP_CODE]) :679-90.
Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, et al. Quantitative 
magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human 
livers. Hepatology  2015;62 (5):1444-55.
Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. International journal of 
molecular sciences 2016;17 (9).
Dietrich P, Hellerbrand C. Non -alcoholic fatt y liver disease, obesity and the metabolic s yndrome. 
Best practice & research 2014;28 (4):637-53.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non -alcoholic fatty  liver disease. 
QJM 2010;103 (2):71-83.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up [Accepted Article]. Hepatology  2014.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up. Hepatology 2015;6 1 (5):1547
-54.
Faramawi MF, Wildman RP, Gustat J, Rice J, Abdul Kareem MY. The association of the 
metabolic sy ndrome with QTc interval in NHANES III. Eur J Epi[INVESTIGATOR_5541] 2008;23 
(7):459-65.
Gao H, Zeng Z, Zhang H, Zhou X, Guan L, Deng W, et al. The Glucagon -Like Peptide-1 
Analogue Liraglutide Inhibits Oxidative Stress and I nflammatory  Response in the 
Liver of Rats with Diet -Induced Non -alcoholic Fatty  Liver Disease. Biological & 
pharmaceutical bulletin 2015;38 (5):694 -702.
Goedeke L, Bates J, Vatner DF, Perry  RJ, Wang T, Ramirez R, et al. Acet yl-CoA Carbox ylase 
Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes 
Hypertrigl yceridemia in Rodents [Accepted Article]. Hepatology 2018.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 112 22 October 2019Hertz R, Bishara -Shieban J, Bar -Tana J. Mode of Action of Peroxis ome Proliferators as 
Hypolipi[INVESTIGATOR_569917]. Suppression of apolipoprotein C -III. J Biol Chem 
1995;270 (22):[ZIP_CODE]-5.
Kim CW, Addy  C, Kusunoki J, Anderson NN, Deja S, Fu X, et al. Acet yl CoA Carboxy lase 
Inhibition Reduces Hepatic Steatosis but Elevates Plasma Trigl ycerides in Mice 
and Humans: A Bedside to Bench Investigation. Cell metabolism 2017;26:[ADDRESS_747718] A. The role of oxidative stress in non -alcoholic steatohepatitis. Clin 
Chim Acta 2011;412 (15- 16):1297-305.
Lee L, Crump M, Khor S, Hoch JS, L uo J, Bremner K, et al. Impact of rituximab on treatment 
outcomes of patients with diffuse large b -cell ly mphoma: a population -based 
analysis. Br J Haematol 2012;158 (4):481-8.
Lee YA, Wallace MC, Friedman SL . Pathobiology of liver fibrosis: a translational success story . 
Gut 2015;64 (5):830-41.
Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance 
elastograph y predicts advanced fibrosis in patients with nonalcoholic fatt y liver 
disease: a prospective study . Hep atology  2014;60 (6):1920 -8.
Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy  JA, et al. Glp- 1 analog, liraglutide, 
ameliorates hepatic steatosis and cardiac h ypertrophy in C57BL/6J mice fed a 
Western diet. American journal of ph ysiology . Gastrointestinal and liver 
physiology  2012;302 (2):G225-35.
Neuschwander -Tetri BA. Hepatic lipotoxicity  and the pathogenesis of nonalcoholic 
steatohepatitis: the central role of nontrigl yceride fatty  acid metabolites. 
Hepatology  2010;52 (2):774-88.
Ong JP, Younossi ZM. Ep idemiology  and natural history  of NAFLD and NASH. Clin L iver Dis 
2007;11 (1):1 -16, vii.
Panjwani N, Mulvihill EE, L onguet C, Yusta B, Campbell JE, Brown TJ, et al. GL P-1 receptor 
activation indirectl y reduces hepatic lipid accumulation but does not attenua te 
development of atherosclerosis in diabetic male ApoE(-/- ) mice. Endocrinology  
2013;154 (1):127 -39.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in 
NAFLD/NASH. Free radical research 2013;47 (11):869 -80.
The EuroQol Group. EuroQol --a new facility  for the measurement of health- related quality  of 
life. . Health Policy  1990;16 (3):199-208.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 113 22 October 2019Vernon G, Baranova A, Younossi ZM. S ystematic review: the epi[INVESTIGATOR_122016]- alcoholic fatty  liver disease and non- alcoholic steatohepatitis in adults. 
Aliment Pharmacol Ther 2011;34 (3):274 -85.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopath y 
in chronic liver disease: 2014 Practice Guideline by [CONTACT_569961]. Hepatology 2014;60 (2):715-35.
Voulgari C, Tentolouris N, Papadogiannis D, Moyssakis I, Perrea D, Ky riaki D, et al. Increased 
left ventricular arrh ythmogenicity  in metabolic syndrome and relationship with 
myocardial performance, risk factors for atherosclerosis, and low -grade 
inflammation. Metabolism: clinical and experimental 2010;59 (2):159 -65.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of 
nonalcoholic fatt y liver disease and nonalcoholic steatohepatitis among a largely 
middle -aged population utilizing ultrasound and liver biopsy : a prospective study . 
Gastroenterology  2011;140 (1):124-31.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapi[INVESTIGATOR_122017] 
U.S. Hepatology  2014;59 (6):2188-95.
Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology  2014;147 
(4):754
-64.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry  L, Wy mer M. Global epi[INVESTIGATOR_569918] y liver disease -Meta -analy tic assessment of prevalence, 
incidence, and outcomes. Hepatology  2016;64 (1):73 -84.
Zhang Y, Lee FY, Bar rera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear 
receptor FXR improves hypergly cemia and hy perlipi[INVESTIGATOR_569919]. Proc 
Natl Acad Sci U S A 2006;103 (4):1006-11.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 114 22 October 201911. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potentia l, and 
Contraceptive Requirements
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE)
Appendix 5. West Haven Criteria
Protocol GS-US-[ADDRESS_747719]. 
Foster City, CA [ZIP_CODE] [LOCATION_003] 
STUDY ACKNO \VLEDGEMENT 
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of 
Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) 
GS-US-454-5533, Amendment 2, 22 October 2019 
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_10883]. 
[P[PD [COMPANY_003] 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated . 
I will provide all study personnel under my supervision copi[INVESTIGATOR_286603] l and access to all 
information provided by [CONTACT_10869], Inc. I will discuss this material with them to ensure 
that they are fully informed abou t the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_569967]1'-.T'fIAL Page [ADDRESS_747720] udy Procedures Table 
Pretr eatment Period Treatment Period 
Kinetic Biomarkers Kinetic B iomarkers 
(Cycle 1) (Cycle 2) 
Day Day Day Day Day Day Day Day 
Day 7 28 56 84 112 140 1 54 157 161 Day 168 
Day Day (WK (WK (WK (WK (WK (WK (WK (WK22 (WK (WK T elephon 
Day -11 - 7 Day 1) 4) 8) 12) 16) 20) 22) Day 2) 23) 24/EOT) e Follow-
Screening - 14 (±Id) (±Id) 1 (±3d) (±3d) (±3d) (±3d) (±3d) (±3d) (±Id) ( ±Id) ( ±Id) (±3d)" ET Up• (±3d) 
Clinical Assess ments 
Written 
lnfom1ed X 
Consent 
Confi m1 X X Eligibility 
Med ical History X X 
PE, V i tal S igns 
including X X X X X X X X X X X 
Weight< 
Fundus X Exam inat iond 
Height X 
[ADDRESS_747721] ionna ires 
Calculate CP X X X X X X X X Score 
D ispense 
Deuterated X X 
Water 
CON FIDENTI AL Page I 1 6 22 October 2019 
Protocol GS-US-454- 5533 
[COMPANY_009] Sciences, Inc. 
D ispense study 
drugs 
Review of 
Deuterated 
Water 
Compliance 
Review of 
Study Drug 
Dosing 
Compliance 
Conco m itant 
Med ications 
Adverse Events 
FibroScan * 
MRI POFF, 
MRE 
Subject Fasting 
Chemistry, 
Hematology, 
Coagu lation Screening 
X 
xr 
xs 
xs 
X 
X 
CON FIDENTI AL Pretr eatment Period Treatment Period 
Kinetic Bioma rkers Kinetic B ioma r kers 
(Cycle 1) (C ycle 2) 
Day Day Day Day Day Day Day Day 
Day 7 28 56 84 112 140 1 54 157 161 
Day Day (WK (WK (WK (WK (WK (WK (WK (WK22 (WK 
Day -11 - 7 Day 1) 4) 8) 12) 16) 20) 22) Day 2) 23) 
- 14 (±Id) (±Id) 1 (±3d) (±3d) (±3d) (±3d) (±3d) (±3d) (±Id) ( ±Id) ( ±Id) 
x• X X X X X 
X X 
X X X X X 
X X X X X X X X X X X X X 
X X X X X X X X X X X X X 
Imaging Assess ments 
11 I 11 I I 1: 1 I I I I I 
Labor ator y Assess ments 
X X X X X X X X X X X X X 
X X X X X X X X 
Page 117 Day 168 
(WK 
24/EOT) 
(±3d)" 
X 
X 
X 
X 
X 
X 
X Final 
Amendment2 
T elephon 
e Follow-
ET Up• (±3d) 
X 
X X 
X X 
X 
X 
22 October 2019 
Protocol GS-US-454-5533 Final 
[COMPANY_009] Sciences, Inc. Amend ment2 
Pretr eatment Period Treatment Period 
Kinetic Bioma rkers Kinetic Bioma rkers 
(Cycle 1) (Cycle 2) 
Day Day Day Day Day Day Day Day 
Day7 28 56 84 112 140 154 157 161 Day 168 
Day Day (WK (WK (WK (WK (WK (WK (WK (WK22 (WK (WK T elephon 
Day -11 - 7 D ay 1) 4) 8) 12) 16) 20) 22) D ay 2) 2 3) 24/EOT) e Follow-
Screening - 14 ( ±Id) (±Id) 1 (±3d) (±3d) (±3d) (±3d) (±3d) (±3d) ( ±Id) (±Id) ( ±Id) (±3d)" ET Up• (±3d) 
Insu lin and X X X X X X x• Lipi[INVESTIGATOR_569920] X X X x• Alc(HbAlc) 
eGFR X X X X X X X X X X X 
HIV I, HBV , X HCV Sero logy 
Calc itonin X 
FibroTest * xs X X x• 
ELF"' Test; X X X x• 
Blood 
Collection X X X X X X X X (Kinetic 
Biomarkers) 
PK Samp ling Xi Xi Xi x; 
Pregnancy 
Test ing' X X X X X X X X X X 
Urine Drug X Screen 
CONFIDENTI AL Page I 18 22 October 2019 
Protocol GS-US-454-5533 
[COMPANY_009] Sciences, Inc. 
Screening Pretr eatment Period 
Day 
- 14 Kinetic Bioma rkers 
(Cycle 1) 
Day 
-11 
(±Id) Day 
-7 
(±Id) Day 7 
(WK 
Day 1) 
1 (±3d) Day 
28 
(WK 
4) 
(±3d) Day 
56 
(WK 
8) 
(±3d) Day 
84 
(WK 
12) 
(±3d) Treatment Period 
Day 
112 
(WK 
16) 
(±3d) Day 
140 
(WK 
20) 
(±3d) Kinetic Bioma rkers 
(Cycle 2) 
Day Day Day 
154 157 161 Day 168 
(WK (WK22 (WK (WK 
22) Day 2) 23) 24/E OT) 
(±Id) (±Id) (±Id) (±3d)" 
a Subjects premature ly discont inuing from the study should comp lete an ET visit wi thin [ADDRESS_747722] dose Final 
Amendment2 
T elephon 
e Follow-
ET Up• (±3d) 
c Comp lete phys ical exam ination to be perfom1ed at Screen ing. Symptom driven phys ical exam ination to be perfom1ed at Day 14, Day I, Day 7 (Week I), Week 4, Week 8, 
Week 12, Wee k 16, Wee k 20 and Week 24 (EOT) or ET visits 
d For subjects with type 2 diabetes (from medical history or from Screen ing Hemog lobin A I c 2;:6.5%) , a fundus exam will be perfom1ed at Screen ing. Fundus exam inations 
re.qu ire pham1aco logical dilation of both pupi[INVESTIGATOR_569909] a digi tal fundus photography camera speci fied for non dilated exam ination. If a f undus exam ination match ing this 
descript ion has been perfom1ed within [ADDRESS_747723] be available prior to Enro llment (Day 14) 
e Subject will take first dose of study dmgs on site at Day I. 
f AE report ing during Screen ing is limited to SAEs and AEs related to study procedures 
g R equired for all subjects. Will not be used to assess e ligibility for subjects that meet inclus ion criteria based on historical liver biopsy. If a FibroScan ® and/o r MRE has been 
perfom1ed within 4 weeks prior to the date of the Screen ing Visit, the procedure does not need to be repeated. Similarly, if an MRI POFF has been perfom1ed within 4 weeks 
prior to the date of the Screen ing Visit and is deemed acceptab le by [CONTACT_64295] l reader , the procedure does not need to be repeated 
h At the discret ion of the Investigator 
ELF"' Test score will not be prov ided to the sites 
j Sing le PK samp le anytime during visit 
k A ll fema les of childbear ing potent ial w ill have a semm pregnancy test at Screen ing. Urine pregnancy testing w ill occu r at Day I (prior to dosing), Week 4, Week 8, Week 12, 
Week 16, Wee k 20 and Week 24 (EOT) or ET visits. All fema les of childbear ing potent ial th at received at least one dose of study dmg will be dispensed a urine pregnancy 
testing kit at the Week 24 (EOT) or ET visit for home testing at the Telephone Follow Up visit. At the Tel ephone Follow Up visit, subjects will be re.quested to report the 
result of the urine pregnancy test 
CONFI DENTIAL Page I 19 22 October 2019 
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 120 22 October 2019Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this 
study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_10822] a female subject of an y age.
b.Definition of Male Fertility
For the purposes of this study , a m ale born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilatera l orchidectomy  or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Cilofexor has not y et been studied in pregnant women. I n the initial dose range -finding studies 
in
pregnant mice and rabbits, there were no effects on embryofetal development other than a
decrease in fetal bod y weights in pregnant rabbits administered 1000 mg/kg/day. The decrease in
fetal bod y weights are likely secondary to maternal toxicity  rather than a direct effect of
cilofexor . The NOAEL for embry ofetal development is 300 mg/kg/day  in mice and 
200mg/kg/day in rabbits. These doses were associated with exposures that are > [ADDRESS_747724] been conducted to evaluate the reproductive toxicity of firsocostat ;
therefore, the reproductive toxicity  of firsocostat in humans is unknown. However, mutant mice
lacking ACC1, one of the targets of firsocostat ,are embry onicall y lethal. Therefore, firsocostat is
contraindicated in pregnancy . Preclinical data in human hepatocy tes indicate that firsocostat is a
mild inducer of CYP3A4 isoenzy mes. Clinical data demonstrates no decrease in exposure of a
representative oral hormonal contraceptive indicating no loss of contraceptive efficacy  is
expected upon administration of firsocostat with hormonal contraceptives.
Protocol GS -US-454-[ADDRESS_747725] y.Due tospecies difference s in yo lk sac anatomy andfunction, and due to the lackof
GLP-1receptor expressi onin cynomo lgus mo nkey yolk sac, this mechanism is considered 
unlikely to be of relevanc e to hu mans. Involvemen t of addit io nal mechanisms cannot be 
excluded. In rabbits and m onkey s,increased number of pregnancy losses and sligh tly increased 
incidences of foetal abnormali ties, which did not resemble the findings in rats, were observed. 
These findings might be incidental or related to the markedl y reduce dmaterna lbody weight; 
however, relevance to humans cannot be comple tely excluded for these findings. There are 
limited data from t
heuseofsemaglu tidein pregnant women. Therefore, semaglu tideshould not
beused during pregnancy. Oral contraceptives are considered effect ive as no clinically  relevant 
decrease in the overall exposure of ethin ylestradi olandlevonorgestre lwas observed when 
co-administered with semaglut ides.c.
Please refer to the latest version of the corresponding Investigator’s Brochure of each compound
for additional information.
3)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They  must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Baseline/Day  1 visit prior to Enrollment unless permanentl y 
sterile or postmenopausal as defined in Appendix 3. Urine p regnancy  tests will be performed at 
monthly  intervals thereafter until week 24 . A urine pregnancy  testing kit will be dispensed at the 
Week 24 (EOT) or ET visit for home testing at the Tele phone Follow -
Up visit. Female subjects 
must agree to one of the following fro m Screening until [ADDRESS_747726] dose of study
drug.
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per ye ar
Intrauterine ho rmone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure®micro -insert s ystem (provided confirmation of success 3 months after procedure)
Vasecto my in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Protocol GS -US-454-[ADDRESS_747727]'s male partner is required. Subjects who utilize a hormonal contraceptive as one 
oftheir birth control methods must have used the same method for at least three months prior to 
study dosing. Hormonal ly-based contraceptives permitted for use in this protocol are as follow s:
Oral contraceptives (either combined or progesterone only)
Injectable progesteron e
Implants of levonorgestrel
Transdermal contraceptive patch
Contraceptive vaginal rin g
Not all of these methods may be approved in each of the countries where thestudy is being 
conducted: please refer to local product information. A dditional local regulatory requirements 
mayapply
.
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least [ADDRESS_747728] dose of study drug.
4) Contraception Requirements for Male Subjects
Itis theoreticall y possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid. Therefore, male subjects with 
female partners of childbearing potential must use condoms during treatment until [ADDRESS_747729] 
one of the above methods.
Male subjects must also refrain from sperm donation during treatment and until at least 
7weeks after the last dose of study drug.
5) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence ( eg,calendar, ovulation, 
symptotherm al, post -ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactat ional amenorrhea method (LAM). Female condom and male condom should not be used 
together.
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 123 22 October [ZIP_CODE]) Procedures to be Followed in the Event of Pregnancy
Subjects will be instruc ted to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within [ADDRESS_747730] report the 
information to the investigator. Instructions for reporting pregnancy, partner pregnancy , and 
pregnancy
 outcome are outlined in Section [IP_ADDRESS].
Protocol GS -US-454-5533 Final
[COMPANY_009] Sciences, Inc. Amendment 2
CONFIDENTIAL Page 124 22 October 2019Appendix 4. Common Terminology Criteria for Adv erse Events (CTCAE) 
Refer to the Site Operations Manual for additional CTCAE information. 
Protocol GS -US-454-[ADDRESS_747731] Haven Criteria 
http://www.mdcalc.com/hepatic -encephalopathy -grades -stages/
Grade of Hepatic 
Encephalopathy Description Suggested Operative Criteria
Grade ITrivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairm ent of addition or 
subtraction
Altered sleep rhythmDespi[INVESTIGATOR_569921] (see 
below ), the patient appears to have some 
cognitive/ behavioral decay with respect to his 
or her standard on clinical examination or to 
the caregivers
Grade IILethargy or apathy
Disorientation for time
Obvious personality change
Inappropriate behavior
Dyspraxia
AsterixisDisoriented for time (at least three of the 
followings are w rong: day of the month, day 
of the week, month, season, or year) ± the 
other mentioned symptoms
Grade IIISomnolence to semistupor
Responsive to stimuli
Confused
Gross disorientation
Bizarre behaviorDisoriented also for space (at least three of the 
following wrong ly reported: country, state 
[orregion], city, or place) ± the other 
mentioned symptoms
Grade IV Com a Does not respond even to painful stimuli
Adapted from {Vilstrup 2014 }